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Preface
The past 2 years have witnessed remarkable advances in the development of an-
tiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection, as well as
measurement of HIV plasma RNA (viral load) to guide the use of antiretroviral drugs.
The use of ART, in conjunction with the prevention of specific HIV-related opportunis-
tic infections (OIs), has been associated with dramatic decreases in the incidence of
OIs, hospitalizations, and deaths among HIV-infected persons.
Advances in this field have been so rapid, however, that keeping up with them has
posed a formidable challenge to health-care providers and to patients, as well as to
institutions charged with the responsibility of paying for these therapies. Thus, the
Office of AIDS Research, the National Institutes of Health, and the Department of
Health and Human Services, in collaboration with the Henry J. Kaiser Foundation,
have assumed a leadership role in formulating the scientific principles (NIH Panel) and
developing the guidelines (DHHS/Kaiser Panel) for the use of antiretroviral drugs that
are presented in this report. CDC staff participated in these efforts, and CDC and
MMWR are pleased to be able to provide this information as a service to its readers.
This report is targeted primarily to providers who care for HIV-infected persons, but
it also is intended for patients, payors, pharmacists, and public health officials. The
report comprises two articles. The first article, Report of the NIH Panel To Define Prin-
ciples of Therapy of HIV Infection, provides the basis for the use of antiretroviral
drugs, and the second article, Guidelines for the Use of Antiretroviral Agents in HIV-
Infected Adults and Adolescents, provides specific recommendations regarding when
to start, how to monitor, and when to change therapy, as well as specific combinations
of drugs that should be considered. Both articles provide cross-references to each
other so readers can locate related information. Tables and figures are included in the
Appendices section that follows each article. Although the principles are unlikely to
change in the near future, the guidelines will change substantially as new information
and new drugs become available.
Copies of this document and all updates are available from the CDC National AIDS
Clearinghouse (1-800-458-5231) and are posted on the Clearinghouse World-Wide
Web site (http://www.cdcnac.org). In addition, copies and updates also are available
from the HIV/AIDS Treatment Information Service (1-800-448-0440; Fax 301-519-6616;
TTY 1-800-243-7012) and on the ATIS World-Wide Web site (http://www.hivatis.org).
Readers should consult these web sites regularly for updates in the guidelines. 
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Report of the NIH Panel To Define Principles of
Therapy of HIV Infection*
Summary
Recent research advances have afforded substantially improved under-
standing of the biology of human immunodeficiency virus (HIV) infection and
the pathogenesis of the acquired immunodeficiency syndrome (AIDS). With the
advent of sensitive tools for monitoring HIV replication in infected persons, the
risk of disease progression and death can be assessed accurately and the effi-
cacy of anti-HIV therapies can be determined directly. Furthermore, when used
appropriately, combinations of newly available, potent antiviral therapies can
effect prolonged suppression of detectable levels of HIV replication and circum-
vent the inherent tendency of HIV to generate drug-resistant viral variants.
However, as antiretroviral therapy for HIV infection has become increasingly ef-
fective, it has also become increasingly complex. Familiarity with recent
research advances is needed to ensure that newly available therapies are used
in ways that most effectively improve the health and prolong the lives of HIV-
infected persons. To enable practitioners and HIV-infected persons to best use
rapidly accumulating new information about HIV disease pathogenesis and
treatment, the Office of AIDS Research of the National Institutes of Health spon-
sored the NIH Panel to Define Principles of Therapy of HIV Infection. This Panel
was asked to define essential scientific principles that should be used to guide
the most effective use of antiretroviral therapies and viral load testing in clinical
practice. Based on detailed consideration of the most current data, the Panel
delineated eleven principles that address issues of fundamental importance for
the treatment of HIV infection. These principles provide the scientific  basis for
the specific treatment recommendations made by the Panel on Clinical Practices
for the Treatment of HIV Infection sponsored by the Department of Health and
Human Services and the Henry J. Kaiser Family Foundation. The reports of both
of these panels are provided in this publication. Together, they summarize new
dta and provide both the scientific basis and specific guidelines for the treatment
of HIV-infected persons. This information will be of interest to health-care
providers, HIV-infected persons, HIV/AIDS educators, public health educators,
public health authorities, and all organizations that fund medical care of HIV-
infected persons.
INTRODUCTION
The past 2 years have brought major advances in both basic and clinical research
on acquired immunodeficiency syndrome (AIDS). The availability of more numerous
and more potent drugs to inhibit human immunodeficiency virus (HIV) replication has
made it possible to design therapeutic strategies involving combinations of an-
tiretroviral drugs that accomplish prolonged and near complete suppression of
*Information included in these principles may not represent FDA approval or approved labeling
for the particular products or indications in question. Specifically, the terms “safe” and “ef-
fective” may not be synonymous with the FDA-defined legal standards for product approval.
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detectable HIV replication in many HIV-infected persons. In addition, more sensitive
and reliable measurements of plasma viral load have been demonstrated to be pow-
erful predictors of a person’s risk for progression to AIDS and time to death. They have
also been demonstrated to reliably assess the antiviral activity of therapeutic agents.
It is now critical that these scientific advances be translated into information that
practitioners and their patients can utilize in making decisions about using the new
therapies and monitoring tools to achieve the greatest, most durable clinical benefits.
Such information will allow physicians to tailor more effective treatments for their
patients and to more closely monitor patients’ responses to specific antiretroviral regi-
mens.
A two-track process was initiated to address this pressing need. The Office of AIDS
Research of the National Institutes of Health (NIH) sponsored the NIH Panel To Define
Principles of Therapy of HIV Infection. This Panel was asked to delineate the scientific
principles, based on its understanding of the biology and pathogenesis of HIV infec-
tion and disease, that should be used to guide the most effective use of antiretroviral
therapy and viral load testing in clinical practice.
The Department of Health and Human Services (HHS) and the Henry J. Kaiser Fam-
ily Foundation sponsored the Panel on Clinical Practices for the Treatment of HIV
Infection. The HHS Panel was charged with developing recommendations, based on
the scientific principles, for the clinical use of antiretroviral drugs and laboratory moni-
toring methods in the treatment of HIV-infected persons. Both documents—the Report
of the NIH Panel To Define Principles of Therapy for HIV Infection, developed by the
NIH Panel, and the Guidelines for the Use of Antiretroviral Agents in HIV-Infected
Adults and Adolescents, developed by the HHS Panel—are provided in this report.
Together, these two documents summarize new data and provide both the scien-
tific basis and specific guidelines for the treatment of HIV-infected persons. The goal
of this report is to assist clinicians and patients in making informed decisions about
treatment options so that a) effective antiretroviral therapy is introduced before exten-
sive immune system damage has occurred; b) viral load monitoring is used as an
essential tool in determining an HIV-infected person’s risk for disease progression and
response to antiretroviral therapy; c) combinations of antiretroviral drugs are used to
suppress HIV replication to below the limits of detection of sensitive viral load assays;
and d) patient adherence to the complicated regimens of combination antiretroviral
therapy that are currently required to achieve durable suppression of HIV replication
is encouraged by patient–provider relationships that provide education and support
concerning the goals, strategies, and requirements of antiretroviral therapy.
The NIH Panel included clinicians, basic and clinical researchers, public health offi-
cials, and community representatives. As part of its effort to accumulate the most
current data, the Panel held a 2-day public meeting to hear presentations by clinicians
and scientists in the areas of HIV pathogenesis and treatment, specifically addressing
the following topics: the relationship between virus replication and disease progres-
sion; the relative ability of available strategies of antiviral therapy to minimize HIV
replication for prolonged periods of time; the relationship between the emergence of
drug resistance and treatment failures; the relative ability of available strategies of
antiviral therapy to delay or prevent the emergence of drug-resistant HIV variants; and
the relationship between drug-induced changes in virus load and improved clinical
outcomes and prolonged survival.
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Summary of the Principles of Therapy of HIV Infection
1. Ongoing HIV replication leads to immune system damage and progression to
AIDS. HIV infection is always harmful, and true long-term survival free of
clinically significant immune dysfunction is unusual.
2. Plasma HIV RNA levels indicate the magnitude of HIV replication and its asso-
ciated rate of CD4+ T cell destruction, whereas CD4+ T cell counts indicate the
extent of HIV-induced immune damage already suffered. Regular, periodic
measurement of plasma HIV RNA levels and CD4+ T cell counts is necessary
to determine the risk for disease progression in an HIV-infected person and to
determine when to initiate or modify antiretroviral treatment regimens.
3. As rates of disease progression differ among HIV-infected persons, treatment
decisions should be individualized by level of risk indicated by plasma HIV
RNA levels and CD4+ T cell counts.
4. The use of potent combination antiretroviral therapy to suppress HIV replica-
tion to below the levels of detection of sensitive plasma HIV RNA assays lim-
its the potential for selection of antiretroviral-resistant HIV variants, the major
factor limiting the ability of antiretroviral drugs to inhibit virus replication and
delay disease progression. Therefore, maximum achievable suppression of
HIV replication should be the goal of therapy.
5. The most effective means to accomplish durable suppression of HIV replica-
tion is the simultaneous initiation of combinations of effective anti-HIV drugs
with which the patient has not been previously treated and that are not cross-
resistant with antiretroviral agents with which the patient has been treated
previously.
6. Each of the antiretroviral drugs used in combination therapy regimens should
always be used according to optimum schedules and dosages.
7. The available effective antiretroviral drugs are limited in number and mecha-
nism of action, and cross-resistance between specific drugs has been docu-
mented. Therefore, any change in antiretroviral therapy increases future
therapeutic constraints.
8. Women should receive optimal antiretroviral therapy regardless of preg-
nancy status.
9. The same principles of antiretroviral therapy apply to HIV-infected children,
adolescents, and adults, although the treatment of HIV-infected children in-
volves unique pharmacologic, virologic, and immunologic considerations.
10. Persons identified during acute primary HIV infection should be treated with
combination antiretroviral therapy to suppress virus replication to levels be-
low the limit of detection of sensitive plasma HIV RNA assays.
11. HIV-infected persons, even those whose viral loads are below detectable lim-
its, should be considered infectious. Therefore, they should be counseled to
avoid sexual and drug-use behaviors that are associated with either transmis-
sion or acquisition of HIV and other infectious pathogens.
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These topics and other data assessed by the Panel in formulating the scientific prin-
ciples were derived from three primary sources: recent basic insights into the life cycle
of HIV, studies of the extent and consequences of HIV replication in infected persons,
and clinical trials of anti-HIV drugs.
In certain instances, the Panel based the principles and associated corollaries on
clinical studies conducted in relatively small numbers of patients for fairly short peri-
ods of time. After carefully evaluating data from these studies, the Panel concluded
that the results of several important contemporary studies have been consistent in
their validation of recent models of HIV pathogenesis.
The Panel believes that new antiretroviral drugs and treatment strategies, if used
correctly, can substantially benefit HIV-infected persons. However, as the under-
standing of HIV disease has improved and the number of available beneficial
therapies has increased, clinical care of HIV-infected patients has become much more
complex. Therapeutic success increasingly depends on a thorough understanding of
the pathogenesis of HIV disease and on familiarity with when and how to use the
more numerous and more effective drugs available to treat HIV infection. The Panel is
concerned that even these new potent antiretroviral therapies will be of little clinical
utility for treated patients unless they are used correctly and that, used incorrectly,
they may even compromise the potential to obtain long-term benefit from other an-
tiretroviral therapies in the future.
The principles and conclusions discussed in this report have been developed and
made available now so that practitioners and patients can make treatment decisions
based on the most current research results. Undoubtedly, insights into the pathogene-
sis of HIV disease will continue to accumulate rapidly, providing new targets for the
development of additional antiretroviral drugs and even more effective treatment
strategies. Thus, the Panel expects that these principles will require modification and
elaboration as new information is acquired.
SCIENTIFIC PRINCIPLES
Principle 1. Ongoing HIV replication leads to immune system damage and progres-
sion to AIDS. HIV infection is always harmful, and true long-term survival free of
clinically significant immune dysfunction is unusual.
Active replication of HIV is the cause of progressive immune system damage in
infected persons (1–10 ). In the absence of effective inhibition of HIV replication by
antiretroviral therapy, nearly all infected persons will suffer progressive deterioration
of immune function resulting in their susceptibility to opportunistic infections (OIs),
malignancies, neurologic diseases, and wasting, ultimately leading to death (11,12 ).
For adults who live in developed countries, the average time of progression to AIDS
after initial infection is approximately 10–11 years in the absence of antiretroviral ther-
apy or with older regimens of nucleoside analog (e.g., zidovudine [ZDV])
monotherapy (11 ). Some persons develop AIDS within 5 years of infection (20%),
whereas others (<5%) have sustained long-term (>10 years) asymptomatic HIV infec-
tion without decline of CD4+ T cell counts to <500cells/mm3. Only approximately 2%
or less of HIV-infected persons seem to be able to contain HIV replication to extremely
low levels and maintain stable CD4+ T cell counts within the normal range for lengthy
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periods (>12 years), and many of these persons display laboratory evidence of im-
mune system damage (12 ). Thus, HIV infection is unusual among human virus
infections in causing disease in such a large proportion of infected persons.
Although a very small number of HIV-infected persons do not demonstrate pro-
gressive HIV disease in the absence of antiretroviral therapy, there is no definitive way
to prospectively identify these persons. Therefore, all persons who have HIV infection
must be considered at risk for progressive disease. The goals of treatment for HIV
infection should be to maintain immune function in as near a normal state as possible,
prevent disease progression, prolong survival, and preserve quality of life by effec-
tively suppressing HIV replication. For these goals to be accomplished, therapy should
be initiated, whenever possible, before extensive immune system damage has oc-
curred.
Principle 2. Plasma HIV RNA levels indicate the magnitude of HIV replication and
its associated rate of CD4+ T cell destruction, whereas CD4+ T cell counts indicate the
extent of HIV-induced immune damage already suffered. Regular, periodic measure-
ment of plasma HIV RNA levels and CD4+ T cell counts is necessary to determine the
risk for disease progression in an HIV-infected person and to determine when to initi-
ate or modify antiretroviral treatment regimens.
The rate of progression of HIV disease is predicted by the magnitude of active HIV
replication (reflected by so-called viral load) taking place in an infected person
(5–10,13–18 ). Measurement of viral load through the use of quantitative plasma HIV
RNA assays permits assessment of the relative risk for disease progression and time
to death (5-10,13–18 ). Plasma HIV RNA measurements also permit assessment of the
efficacy of antiretroviral therapies in individual patients (1,2,13,19–25 ). It is expert
opinion that these measurements are necessary components of treatment strategies
designed to use antiretroviral drugs most effectively. The extent of immune system
damage that has already occurred in an HIV-infected person is indicated by the CD4+
T cell count (11,26–29 ), which permits assessment of the risk for developing specific
OIs and other sequelae of HIV infection. When used in concert with viral load determi-
nations, assessment of CD4+ T cell number enhances the accuracy with which the risk
for disease progression and death can be predicted (27 ). Issues specific for the labo-
ratory assessment of plasma HIV RNA and CD4+ T cell levels in HIV-infected infants
and young children are discussed in Principle 9 (14–18,25,30 ). Important specific con-
siderations regarding laboratory evaluations and HIV-infected persons include the
following:
1. In the newly diagnosed patient, baseline plasma HIV RNA levels should be
checked in a clinically stable state. Plasma HIV RNA levels obtained within the
first 6 months of initial HIV infection do not accurately predict a person’s risk for
disease progression (31 ). In contrast, plasma HIV RNA levels stabilize (reach a
“set-point”) after approximately 6–9 months of initial HIV infection and are then
predictive of risk for disease progression (5–10 ). Following their stabilization,
plasma HIV RNA levels may remain fairly stable for months to years in many
HIV-infected persons (7,10 ). However, immunizations and intercurrent infec-
tions can lead to transient elevations of plasma HIV RNA levels (32–34 ). As a
result, values obtained within approximately 4 weeks of such episodes may not
accurately reflect a person’s actual baseline plasma HIV RNA level. For an accu-
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rate baseline, two specimens obtained within 1–2 weeks of each other, pro-
cessed according to optimal, validated procedures, and analyzed by the same
quantitative method are recommended. The use of two baseline measurements
serves to reduce the variance in the plasma HIV RNA assays that results from
technical and biologic factors (19,22,35,36 ).
2. Studies of populations of HIV-infected persons indicate that plasma HIV RNA
levels gradually increase with time after infection (10 ). A steeper rate of increase
is associated with an increased risk of disease progression. Within individual
patients, the actual rate of change of plasma HIV RNA levels is unpredictable but
can increase abruptly. Therefore, periodic monitoring of plasma HIV RNA levels
is necessary to accurately gauge risk of disease progression. (See Guidelines.)
3. Studies of the kinetics of HIV replication in infected persons indicate that levels
of plasma HIV RNA should measurably decline within days of initiation of effec-
tive combination antiretroviral therapy (1,2,20,21,37 ). In patients in whom ces-
sation of detectable new rounds of HIV infection of CD4+ T cells occurs, plasma
HIV RNA levels should fall to approximately 1% of their initial levels within
2 weeks after initiation of therapy, reaching a nadir (ideally below the limit of
detection of sensitive plasma HIV RNA assays) within approximately 8 weeks.
Persons who have very high initial plasma HIV RNA levels may take longer to
reach a nadir of plasma RNA levels following initiation of effective antiretroviral
therapy (up to approximately 16 weeks). (See Guidelines.)
4. Plasma HIV RNA assays provide the best measure of the activity of antiretroviral
therapy of HIV-infected persons. Rebound of plasma HIV RNA levels following
their suppression by antiretroviral therapy may indicate the outgrowth of drug-
resistant HIV variants in a patient adherent to the regimen (see Principle 7 for
additional considerations). Should the desired level of suppression of HIV repli-
cation be accomplished in treated patients by 16 weeks after initiation or altera-
tion of an antiretroviral regimen, plasma HIV RNA levels should be checked
periodically to document the continued activity of the chosen antiretroviral regi-
men.
5. HIV RNA levels can vary by approximately threefold (0.5 log10) in either direc-
tion, upon repeated measurements (obtained withing days or weeks of each
other) in clinically stable, HIV-infected persons (19,22,35,36 ). Changes greater
than 0.5 log10 usually cannot be explained by inherent biological or assay vari-
ability and likely reflect a biologically and clinically relevant change in the level
of plasma HIV RNA. It is important to note that the variability of the current
plasma HIV RNA assays is greater toward their lower limits of sensitivity. Thus,
differences between repeated measures of greater than 0.5 log10 may be seen at
very low plasma HIV RNA values and may not reflect a substantive biological or
clinical change.
6. CD4+ T cell counts should be obtained for all patients who have newly diag-
nosed HIV infection (28,29 ) (See Guidelines).
7. CD4+ T cell counts are subject to substantial variability due to both biological
and laboratory methodologies (26 ) and can vary up to 30% on repeated meas-
ures in the absence of a change in clinical status. Thus, it is important to monitor
trends over time rather than base treatment decisions on one specific determi-
nation.
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8. In patients who are not receiving antiretroviral therapy, CD4+ T cell counts
should be checked regularly to monitor patients for evidence of disease progres-
sion. (See Guidelines.)
9. In patients receiving antiretroviral therapy, CD4+ T cell counts should be checked
regularly to document continuing immunologic benefit and to assess the current
degree of immunodeficiency (28,29 ). (See Guidelines.)
10. It is not yet known whether a given CD4+ T cell level achieved in response to
antiretroviral therapy provides an equivalent assessment of the degree of im-
mune system function or has the same predictive value for risk for OIs as do
CD4+ T cell levels obtained in the absence of therapy. The potentially incomplete
recovery of T cell function and the diversity of antigen recognition, despite CD4+
T cell increases induced by antiretroviral therapy, have raised concerns that pa-
tients may remain susceptible to OIs at higher CD4+ T cell levels. Until more data
concerning this issue are available, the Panel concurs with recent U.S. Public
Health Service/Infectious Diseases Society of America recommendations that
prophylactic medications be continued when CD4+ T cell counts increase above
recommended threshold levels as a result of initiation of effective antiretroviral
therapies (i.e., that the provision of prophylaxis be based on the lowest reliably
determined CD4+ T cell count) (28 ).
11. Measurements of p24 antigen, neopterin, and β-2 microglobulin levels have
often been used to assess risk for disease progression. However, these measure-
ments are less reliable than plasma HIV RNA assays and do not add clinically
useful prognostic information to that obtained from HIV RNA and CD4+ T cell
levels. As such, these laboratory tests need not be included as part of the routine
care of HIV-infected patients.
Principle 3. As rates of disease progression differ among HIV-infected persons,
treatment decisions should be individualized by level of risk indicated by plasma HIV
RNA levels and CD4+ T cell counts.
Decisions regarding when to initiate antiretroviral therapy in an HIV-infected per-
son should be based on the risk for disease progression and degree of
immunodeficiency. Initiation of antiretroviral therapy before the onset of immunologic
and virologic evidence of disease progression is expected to have the greatest and
most durable beneficial impact on preserving the health of HIV-infected persons.
When specific viral load or CD4+ T cell levels at which therapy should be initiated are
considered, it is important to recognize that the risk for disease progression is a con-
tinuous rather than discrete function (5,6,10,27 ). There is no known absolute
threshold of HIV replication below which disease progression will not eventually oc-
cur. At present, recommendations for initiation of therapy must be based on the fact
that the types and numbers of available antiretroviral drugs are limited. When more
numerous, more effective, better tolerated, and more conveniently dosed drugs be-
come available, it is likely that indications for initiation of therapy will change
accordingly. Specific considerations regarding treatment include the following:
1. Decisions made by health-care practitioners and HIV-infected patients regarding
initiation of antiretroviral therapy should be guided by the patient’s plasma HIV
RNA level and CD4+ T cell count. (See Guidelines.)
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2. Data are not yet available that define the degree of therapeutic benefit in per-
sons who have relatively high CD4+ T cell counts and relatively low plasma HIV
RNA levels (e.g., CD4+ T cell count >500/mm3 and plasma HIV RNA <10,000 cop-
ies/mL). However, emerging insights into the pathogenesis of HIV disease pre-
dict that antiretroviral therapy should be of benefit to such patients. For persons
at low risk for disease progression, decisions concerning when to initiate an-
tiretroviral therapy must also include consideration of the potential inconven-
ience and toxicities of the available antiretroviral drugs. Should the decision be
made to defer therapy, regular monitoring of HIV RNA levels and CD4+ T cell
counts should be performed as recommended (See Guidelines).
3. Persons who have levels of HIV RNA persistently below the level of detection of
currently available HIV RNA assays and who have stable, high CD4+ T cell
counts in the absence of therapy are at low risk for disease progression in the
near future. The potential for benefit of treatment for these persons is not
known. Should the decision be made to defer therapy, regular monitoring of HIV
RNA levels and CD4+ T cell counts should be performed as recommended (see
Guidelines).
4. Patients who have late-stage disease (as indicated by clinical evidence of ad-
vanced immunodeficiency or low CD4+ T cell counts, e.g., <50 cells/mm3) have
benefited from appropriate antiretroviral therapy as evidenced by decreased
risks for further disease progression or death (23,28 ). In such patients, an-
tiretroviral therapy can be of benefit even when CD4+ T cell increases are not
seen. Therefore, discontinuation of antiretroviral therapy in this setting should
be considered only if available antiretroviral therapies do not suppress HIV rep-
lication to a measurable degree, if drug toxicities outweigh the anticipated clini-
cal benefit, or if survival and quality of life are not expected to be improved by
antiretroviral therapy (e.g., terminally ill persons).
Principle 4. The use of potent combination antiretroviral therapy to suppress HIV
replication to below the levels of detection of sensitive plasma HIV RNA assays limits
the potential for selection of antiretroviral-resistant HIV variants, the major factor
limiting the ability of antiretroviral drugs to inhibit virus replication and delay disease
progression. Therefore, maximum achievable suppression of HIV replication should
be the goal of therapy.
Studies of the biology and pathogenesis of HIV infection have provided the basis
for using antiretroviral drugs in ways that yield the most profound and durable sup-
pression of HIV replication. The inherent ability of HIV to develop drug resistance
represents the major obstacle to the long-term efficacy of antiretroviral therapy (21 ).
However, recent clinical evidence indicates that the development of drug resistance
can be delayed, and perhaps even prevented, by the rational use of combinations of
drugs that include newly available, potent agents to suppress HIV replication to levels
that cannot be detected by sensitive assays of plasma HIV RNA (23,38–40 ). Cessation
of detectable HIV replication decreases the opportunity for accumulation of mutations
that may give rise to drug-resistant viral variants. Furthermore, the extent and dura-
tion of inhibition of HIV replication by antiretroviral therapy predicts the magnitude of
clinical benefit derived from treatment (9,13,23–25 ).
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The potential toxicities of therapy, as well as the patient’s quality of life and ability
to adhere to a complex antiretroviral drug regimen, should be balanced with the an-
ticipated clinical benefit of maximal suppression of HIV replication and the anticipated
risks of less complete suppression. Specific considerations regarding treatment in-
clude the following:
1. Once a decision has been made to initiate antiretroviral therapy, the ideal goal of
therapy should be suppression of the level of active HIV replication, as assessed
by sensitive measures of plasma HIV RNA, to undetectable levels.
2. If suppression of HIV replication to undetectable levels cannot be achieved, the
goal of therapy should be to suppress virus replication as much as possible for
as long as possible. Less complete suppression of HIV replication is expected to
yield less profound and less durable immunologic and clinical benefits. Higher
residual levels of HIV replication during therapy predispose the patient to more
rapid development of antiretroviral drug resistance and associated waning of
clinical benefit. In the absence of effective suppression of detectable HIV replica-
tion, it is currently impossible to identify a precise target level for suppression of
HIV replication that will yield predictable clinical benefits. However, recent data
indicate that suppression of HIV RNA levels to <5,000 copies/mL is likely to yield
more greater and more durable clinical benefit than less complete suppression
(24 ).
3. The HIV RNA assays currently available have similar levels of sensitivity (19,41–
46 ; Table). More sensitive versions of each of these assays are currently in de-
velopment and will likely be commercially available in the future. Once these
assays are available, the goal of antiretroviral therapy should be suppression of
HIV RNA levels to below detection of these more sensitive assays. Less pro-
found suppression of HIV replication is associated with a greater likelihood of
development of drug resistance (23,40 ).
4. Although suppression of HIV load to levels below the detection limits of sensi-
tive plasma HIV RNA assays indicates profound inhibition of new cycles of virus
replication, it does not mean that the infection has been eradicated or that virus
replication has been stopped completely (37,47–50 ). HIV replication may be
continuing in various tissues (e.g., the lymphatic tissues and the central nervous
system) although it can no longer be detected by plasma HIV RNA assays.
Strategies for potential eradication are being pursued in experimental studies,
but the likelihood of their success is uncertain (37,51 ). Recent studies indicate
that infectious HIV can still be isolated from CD4+ T cells obtained from infected
persons whose plasma HIV RNA levels have been suppressed below detection
for prolonged periods (up to 30 months) (49,50 ). Long-term persistence of HIV
infection in such persons who have undetectable levels of plasma HIV RNA ap-
pears to be due to the existence of long-lived reservoirs of latently infected CD4+
cells, rather than drug failure (49,50 ). Continued monitoring of HIV RNA levels is
necessary in patients who have achieved antiretroviral drug-induced suppres-
sion of HIV RNA to undetectable levels, as this effect may be transient. (See
Guidelines.)
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Principle 5. The most effective means to accomplish durable suppression of HIV
replication is the simultaneous initiation of combinations of effective anti-HIV drugs
with which the patient has not been previously treated and that are not cross-
resistant with antiretroviral agents with which the patient has been previously
treated.
Several issues should be considered regarding the combination of antiretroviral
drugs to be used in the treatment of an HIV-infected patient. The efficacy of a given
regimen of combination antiretroviral therapy is not simply a function of the number
of drugs used. The most effective antiretroviral drugs possess high potency, favorable
pharmacologic properties, and require that HIV acquire multiple mutations in the rele-
vant HIV target gene before high-level drug resistance is realized. In addition,
drug-resistant HIV variants selected for by treatment with certain antiretroviral drugs
may display diminished ability to replicate (decreased “fitness”) in infected persons
(21 ). Drugs used in combination should show evidence of additivity or synergy of
antiretroviral activity, should lack antagonistic pharmacokinetic or antiretroviral prop-
erties, and should possess nonoverlapping toxicities. Ideally, the chosen drugs will
display molecular interactions that increase the potency of antiretroviral therapy or
delay the emergence of antiretroviral drug resistance. If multiple options are available
for combination therapy, specific antiretroviral drugs should be employed so that fu-
ture therapeutic options are preserved if the initial choice of therapy fails to achieve its
desired result. Whenever possible, therapy should be initiated or modified with a ra-
tional combination of antiretroviral drugs, a predefined target for the degree of
suppression of HIV replication desired, and a predefined alternative antiretroviral regi-
men to be used should the target goal not be reached. Specific considerations
regarding treatment include the following:
1. The combination of antiretroviral drugs used when therapy is either initiated or
changed needs to be carefully chosen because it will influence subsequent op-
tions for effective antiretroviral therapy if the chosen drug regimen fails to ac-
complish satisfactory suppression of HIV replication.
2. The best opportunity to accomplish maximal suppression of virus replication,
minimize the risk of outgrowth of drug-resistant HIV variants, and maximize pro-
tection from continuing immune system damage is to use combinations of ef-
fective antiretroviral drugs in persons who have no prior history of anti-HIV
therapy.
3. No single antiretroviral drug that is currently available, even the more potent
protease inhibitors (PIs), can ensure sufficient and durable suppression of HIV
replication when used as a single agent (“monotherapy”). Furthermore, the use
of potent antiretroviral drugs as single agents presents a great risk for the devel-
opment of drug resistance and the potential development of cross-resistance to
related drugs. Thus, antiretroviral monotherapy is no longer a recommended
option for treatment of HIV-infected persons (see Guidelines). One exception is
the use of zidovudine (ZDV) according to the AIDS Clinical Trials Group (ACTG)
076 regimen. This regimen is specifically for the purpose of reducing the risk for
perinatal HIV transmission in pregnant women who have high CD4+ T cell
counts and low plasma HIV RNA levels and who have not yet decided to initiate
antiretroviral therapy based on their own health indications (52–54 ). This time-
limited use of zidovudine by a pregnant woman to prevent perinatal HIV trans-
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mission has important benefits to infants and is not likely to substantially com-
promise her future ability to benefit from combination antiretroviral therapy.
4. Antiretroviral drugs (e.g., lamivudine [3TC]) or the non-nucleoside reverse trans-
criptase inhibitors (NNRTIs; e.g., nevirapine and delavirdine), that are potent, but
to which HIV readily develops high-level resistance, should not be used in regi-
mens that are expected to yield incomplete suppression of detectable HIV repli-
cation.
5. At present, durable suppression of detectable levels of HIV replication is best
accomplished with the use of two nucleoside analog reverse transcriptase (RT)
inhibitors combined with a potent PI. In patients who have not been treated with
antiretroviral therapy, suppression of detectable HIV replication has also been
reported with the use of two nucleoside analog RT inhibitors combined with a
NNRTI (e.g., zidovudine, didanosine, and nevirapine [40 ]). However, the role of
this approach as initial antiretroviral therapy needs to be better defined before it
can be recommended as a “first-line” treatment strategy. Furthermore, this ap-
proach is considerably less effective in persons who have been previously
treated with nucleoside analog RT inhibitors (55–57 ). In the subset of previously
treated patients who respond initially to such regimens, suppression of HIV rep-
lication is often transient and the associated clinical benefit is limited.
6. The use of fewer than three antiretroviral drugs in combination may be consid-
ered as an option by HIV-infected persons and their physicians. In making this
decision, it is important to recognize that no combination of two currently avail-
able nucleoside analog RT inhibitors has been demonstrated to consistently pro-
vide sufficient and durable suppression of HIV replication. Although the initial
decline in HIV RNA levels following treatment with two RT inhibitors may be
encouraging, the durability of the response beyond 24–48 weeks in controlled
studies has been disappointing (40,56–60 ). Furthermore, the selection of drug-
resistant HIV variants by antiretroviral regimens that fail to suppress HIV replica-
tion durably may compromise the range of future treatment options. Even in
antiretroviral-drug–naive patients, the use of NNTRIs is not routinely recom-
mended in combination with one nucleoside analog RT inhibitor, as the risk for
selection of NNRTI-resistant HIV variants is high in regimens that fail to achieve
suppression of detectable HIV replication (1,61 ). Certain combinations of two
protease inhibitors (without added RT inhibitors) have been reported to provide
suppression of detectable HIV replication in pilot studies (62,63 ); however, given
the limited experience available with this approach, it should not be considered
as a first-line regimen at the present time. (See Guidelines.)
7. When a change in therapy is considered in a previously treated patient, a review
of the person’s prior history of anti-HIV therapy is essential. Drugs chosen as the
components of a new antiretroviral regimen should not be cross-resistant to
previously used antiretroviral drugs (or share similar patterns of mutations as-
sociated with antiretroviral drug resistance). (See Principle 7 for additional con-
siderations.)
8. When changing a failing regimen, it is important to change more than one com-
ponent of the regimen. The addition of single antiretroviral agents, even very
potent ones, is likely to lead to the development of viral resistance to the new
agent. (See Guidelines.)
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Principle 6. Each of the antiretroviral drugs used in combination therapy regimens
should always be used according to optimum schedules and dosages.
The use of combinations of potent antiretroviral drugs to exert constant, maximal
suppression of HIV replication provides the best approach to circumvent the inherent
tendency of HIV to generate drug-resistant variants. Specific considerations regarding
treatment include the following:
1. Combination therapy should be initiated with all drugs started simultaneously
(ideally within 1 or 2 days of each other); antiretroviral therapies should not be
added sequentially. Staged introduction of individual antiretroviral drugs in-
creases the likelihood that incomplete suppression of HIV replication will be
achieved, thereby permitting the progressive accumulation of mutations that
confer resistance to multiple antiretroviral agents. Rather than strive to increase
patient acceptance of therapy through the sequential addition of antiretroviral
drugs, the Panel believes it is better to counsel and educate patients extensively
before the initiation of antiretroviral therapy, even if it means a limited delay in
initiating treatment.
2. Whenever possible, combination antiretroviral therapy should be maintained at
recommended drug doses. At any time after initiation of therapy, underdosing
with any one agent in a combination, or the administration of fewer than all
drugs of a combination at any one time, should be avoided. Antiretroviral drug
resistance is less likely to occur if all antiretroviral therapy is temporarily
stopped than if the dosage of one or more components is reduced or if one com-
ponent of an effective suppressive regimen is withheld. Should antiretroviral
drug resistance develop as a result of underdosing or irregular dosing of an-
tiretroviral drugs, subsequent readministration of recommended doses of drugs
on a regular schedule is unlikely to accomplish effective suppression of HIV rep-
lication.
3. Patient adherence to an antiretroviral regimen is critical to the success of ther-
apy. If antiretroviral drugs are used in inadequate doses or are used only inter-
mittently, the risk for developing drug-resistant HIV variants is greatly increased.
Effective adherence to complicated medical regimens requires extensive patient
education about the goals and rationale for therapy before it is initiated, as well
as an ongoing, active collaboration between practitioner and patient when ther-
apy has been started. Counseling should include careful review of the drug-
dosing intervals, the possibility of co-administration of several medications at
the same time, and the relationship of drug dosing to meals and snacks.
4. Available effective regimens of combination antiretroviral therapy require that
patients take multiple medications at specific times of the day. Persons who
have unstable living situations or limited social support mechanisms may have
difficulty adhering to the recommended antiretroviral therapy regimens and
may need special support from health-care workers to do so effectively. If cir-
cumstances impede adherence to the most effective antiretroviral regimens
now available, therapy is unlikely to be of long-term benefit to the patient and
the risk of selection of drug-resistant HIV variants is increased. Therefore, it is
important to ensure that adequate social support is available for patients who
are offered combination antiretroviral therapy. Health-care providers should
work with HIV-infected patients to assess if they are ready and able to commit to
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a regimen of antiviral therapy. Health-care providers should make such assess-
ment on an individual basis and not consider that any specific group of persons
are unable to adhere.
Principle 7. The available effective drugs are limited in number and mechanism of
action, and cross-resistance between specific drugs has been documented. There-
fore, any change in antiretroviral therapy increases future therapeutic constraints.
Decisions to alter therapy will rely heavily on consideration of clinical issues and on
the number of available alternative antiretroviral agents. Every decision made to alter
therapy may limit future treatment options. Thus, available agents should not be
abandoned prematurely. It is not known definitively whether the pathogenic conse-
quences of a measurable level of HIV replication while on therapy are equivalent to
those of an equivalent level in an untreated person; however, preliminary data sug-
gest that this is the case. Thus, the level at which HIV replication continues while on an
antiretroviral drug regimen that has failed to suppress plasma HIV RNA to below de-
tectable levels should be considered as an indication of the urgency with which an
alteration in therapy should be pursued. Specific considerations regarding treatment
include the following:
1. Increasing levels of plasma HIV RNA in a person receiving antiretroviral therapy
can be caused by several factors. Identification of the responsible factor, wher-
ever possible, is an important goal. Evidence of increased levels of HIV replica-
tion may signal the emergence of drug-resistant HIV variants, incomplete
adherence to the antiretroviral therapy, decreased absorption of antiretroviral
drugs, altered drug metabolism due to physiologic changes or drug-drug inter-
actions, or intercurrent infection.
2. Before the decision is made to alter antiretroviral therapy because of an increase
in plasma HIV RNA, it is important to repeat the plasma HIV RNA measurements
to avoid unnecessary changes based on misleading or spurious plasma HIV
RNA values (e.g., the presence of intercurrent infection or imperfect adherence
to therapy).
3. Antiretroviral therapy should be changed when plasma HIV RNA again becomes
detectable (repeatedly and in the absence of events such as imperfect adherence
to the regimen, immunizations, or intercurrent infections that may lead to tran-
sient elevations of plasma HIV RNA levels) and continues to rise in a patient in
whom it had been previously suppressed to undetectable levels. In a person
whose plasma HIV RNA levels had been previously incompletely suppressed,
progressively increasing plasma HIV RNA levels should prompt consideration of
a change in antiretroviral therapy. (See Guidelines.)
4. Evidence of antiretroviral drug toxicity or intolerance is also an important reason
to consider changes in drug therapy. In certain instances, these manifestations
may be transient, and therapy may be safely continued with attention to patient
counseling and continuing evaluation. When it is necessary to change therapy
for reasons of toxicity or intolerance, alternative antiretroviral drugs should be
chosen based on their anticipated efficacy and lack of similar toxicities. In this
situation, substitution of one drug (ideally of the same class and possessing
equal or greater antiretroviral activity) for another, while continuing the other
components of the regimen, is reasonable.
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Principle 8. Women should receive optimal antiretroviral therapy regardless of
pregnancy status.
The use of antiretroviral treatment in HIV-infected pregnant women raises impor-
tant, unique concerns (64 ). HIV counseling and the offer of HIV testing to pregnant
women have been universally recommended in the United States and are now man-
datory in some states. A greater awareness of issues surrounding HIV infection in
pregnant women has resulted in an increased number of women whose initial diagno-
sis of HIV infection is made during pregnancy. In this circumstance, or when women
already aware of their HIV infection become pregnant, treatment decisions should be
based on the current and future health of the mother, as well as on preventing peri-
natal transmission and ensuring the health of the fetus and neonate. Care of the
HIV-infected pregnant woman should involve a collaboration between the HIV special-
ist caring for the woman when she is not pregnant, her obstetrician, and the woman
herself. Treatment recommendations for HIV-infected pregnant women are based on
the belief that therapies of known benefit to women should not be withheld during
pregnancy unless there are known adverse effects on the mother, fetus, or infant that
outweigh the potential benefit to the woman (64 ). There are two separate but inter-
connected issues regarding antiretroviral treatment during pregnancy: a) use of
antiretroviral therapy for maternal health indications and b) use of antiretroviral drugs
for reducing the risk of perinatal HIV transmission. Although zidovudine monotherapy
substantially reduces the risk of perinatal HIV transmission, appropriate combinations
of antiretroviral drugs should be administered if indicated on the basis of the mother’s
health. In general, pregnancy should not compromise optimal HIV therapy for the
mother. Specific considerations regarding treatment of pregnant women include the
following:
1. Recommendations regarding the choice of antiretroviral agents in pregnant
women are subject to unique considerations, including potential changes in
dose requirements due to physiologic changes associated with pregnancy and
potential effects of the drug on the fetus and neonate (e.g., placental passage of
drug and preclinical data indicating potential for teratogenicity, mutagenicity, or
carcinogenicity). (See Guidelines.)
2. No long-term safety studies are available regarding the use of any antiretroviral
agents during pregnancy. Because the first trimester of pregnancy (i.e., weeks
1–14) is the most vulnerable time with respect to teratogenicity (particularly the
first 8 weeks), it may be advisable to delay, when feasible, the initiation of an-
tiretroviral therapy until 14 weeks’ gestational age. However, if clinical, virologic,
or immunologic parameters are such that therapy would be recommended for
nonpregnant persons, many experts would recommend initiating therapy, re-
gardless of gestational age. 
3. Women who are already receiving antiretroviral therapy at the time that preg-
nancy is diagnosed should continue their therapy. Alternatively, if pregnancy is
anticipated or discovered early in the first trimester (before 8 weeks), concern for
potential teratogenicity may lead some women to consider stopping antiretrovi-
ral therapy until 14 weeks’ gestation. Although the effects of all antiretroviral
drugs on the developing fetus during the first trimester are uncertain, most ex-
perts recommend continuation of a maximally suppressive regimen even during
the first trimester. Currently, insufficient data exist to support or refute concerns
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about potential teratogenicity. If antiretroviral therapy is discontinued for any
reason during the first trimester, all agents should be discontinued simultane-
ously. Once they are reinstituted, they should be reintroduced simultaneously.
4. Treatment of a pregnant woman with an antiretroviral regimen that does not
suppress HIV replication to below detectable levels is likely to result in the devel-
opment of antiretroviral drug-resistant HIV variants and limit her ability to re-
spond favorably to effective combination therapy regimens in the future. The
emergence of drug-resistant HIV variants during incomplete suppression of HIV
replication in a pregnant woman may limit the ability of those same antiretrovi-
ral drugs to effectively decrease the risk of perinatal transmission if provided
intrapartum and/or to the neonate.
5. Transmission of HIV from mother to infant can occur at all levels of maternal
viral loads, although higher viral loads tend to be associated with an increased
risk of transmission (53,65 ). Zidovudine therapy is effective at reducing the risk
for perinatal HIV transmission regardless of maternal viral load (53,54 ). There-
fore, use of the recommended regimen of zidovudine alone or in combination
with other antiretroviral drugs should be discussed with and offered to all HIV-
infected pregnant women, regardless of their plasma HIV RNA level (54 ).
Principle 9. The same principles of antiretroviral therapy apply to HIV-infected chil-
dren, adolescents, and adults, although the treatment of HIV-infected children
involves unique pharmacologic, virologic, and immunologic considerations.
Most of the data that support the principles of antiretroviral therapy outlined in this
document have been generated in studies of HIV-infected adults. Adolescents infected
with HIV sexually or through drug use appear to follow a clinical course similar to
adults, and recommendations for antiretroviral therapy for these persons are the
same as for adults (see Guidelines). However, although fewer data are available con-
cerning treatment of HIV infection in younger persons, it is unlikely that the
fundamental principles of HIV disease differ for HIV-infected children. Furthermore,
the data that are available from studies of HIV-infected infants and children indicate
that the same fundamental virologic principles apply, and optimal treatment ap-
proaches are also likely to be similar (14–18,25 ). Therefore, HIV-infected children, as
previously described for HIV-infected adults, should be treated with effective combi-
nations of antiretroviral drugs with the intent of accomplishing durable suppression of
detectable levels of HIV replication.
Unfortunately, not all of the antiretroviral drugs that have demonstrated efficacy in
combination therapy regimens in adults are available in formulations (e.g., palatable
liquid formulations) for infants and young children (particularly for those aged <2
years). In addition, pharmacokinetic and pharmacodynamic studies of some an-
tiretroviral agents have yet to be completed in children. Thus, effective antiretroviral
therapies should be studied in children and age-specific pharmacologic properties of
these therapies should be defined. Antiretroviral drugs selected to treat HIV-infected
children should be used only if their pharmacologic properties have been defined in
the relevant age group of the patient. Use of antiretroviral drugs before these proper-
ties have been defined may result in undesirable toxicities without virologic or clinical
benefit.
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Identification of HIV-infected infants soon after delivery or during the first few
weeks following their birth provides opportunities for treatment of primary HIV infec-
tion and, perhaps, for facilitating the most effective treatment responses (16–18,66 ).
Thus, identification of HIV-infected women through voluntary testing, provision of an-
tiretroviral therapy to the mother and infant to decrease the risk of maternal-infant
transmission, and careful screening of infants born to HIV-infected mothers for evi-
dence of HIV infection will provide an effective strategy to ameliorate the risk and
consequences of perinatal HIV infection.
The specific HIV RNA and CD4+ T cell criteria used for making decisions about
when to initiate therapy in infected adults do not apply directly to newborns, infants,
and young children (14–18 ). As with adults, higher levels of plasma HIV RNA are as-
sociated with a greater risk of  disease progression and death in infants and young
children (14–18 ). However, absolute levels of plasma HIV RNA observed during the
first years of life in HIV-infected children are frequently higher than those found in
adults infected for similar lengths of time, and establishment of a post-primary–infec-
tion set-point takes substantially longer in infected children (15–18 ). The increased
susceptibility of children to OIs, particularly Pneumocystis carinii pneumonia (PCP), at
higher CD4+ T cell counts than HIV-infected adults (30 ) further indicates that the CD4+
T cell criteria suggested as guides for initiation of antiretroviral therapy in HIV-infected
adults are not appropriate to guide therapeutic decisions for infected children. In all,
the need for and potential benefits of early institution of effective antiretroviral ther-
apy are likely to be even greater in children than adults, suggesting that most, if not
all, HIV-infected children should be treated with effective combination antiretroviral
therapies.
Principle 10. Persons identified during acute primary HIV infection should be
treated with combination antiretroviral therapy to suppress virus replication to levels
below the limit of detection of sensitive plasma HIV RNA assays.
Studies of HIV pathogenesis provide theoretical support for the benefits of an-
tiretroviral therapy for persons diagnosed with primary HIV infection, and data that
are accumulating from small-scale clinical studies are consistent with these predic-
tions (49,66–73 ). Results from studies suggest that antiretroviral therapy during
primary infection may preserve immune system function by blunting the high level of
HIV replication and immune system damage occurring during this period and poten-
tially reducing set-point levels of HIV replication, thereby favorably altering the
subsequent clinical course of the infection; however, this outcome has yet to be for-
mally demonstrated (51,73 ). It has been further suggested that the best opportunity to
eradicate HIV infection might be provided by the initiation of potent combination an-
tiretroviral therapy during primary infection (51 ).
The Panel believes that, although the long-term benefits of effective combination
antiretroviral therapy of primary infection are not known, it is a critical topic of inves-
tigation. Therefore, enrollment of newly diagnosed patients in clinical trials should be
encouraged to help in defining the optimal approach to treatment of primary infection.
When this is neither feasible nor desired, the Panel believes that combination an-
tiretroviral therapy with the goal of suppression of HIV replication to undetectable
levels should be pursued. The Panel believes that suppressive antiretroviral therapy
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for acute primary HIV infection should be continued indefinitely until clinical trials pro-
vide data to establish the appropriate duration of therapy.
Principle 11. HIV-infected persons, even those whose viral loads are below detect-
able limits. Therefore, they should be considered infectious. Therefore, they should
be counseled to avoid sexual and drug-use behaviors that are associated with either
transmission or acquisition of HIV and other infectious pathogens.
No data are available concerning the ability of HIV-infected persons who have an-
tiretroviral therapy-induced suppression of HIV replication to undetectable levels
(assessed by plasma HIV RNA assays) to transmit the infection to others. Similarly,
their ability to acquire a multiply resistant HIV variant from another person remains a
possibility. HIV-infected persons who are receiving antiretroviral therapy continue to
be able to transmit serious infectious diseases to others (e.g., hepatitis B and C and
sexually transmitted infections, such as herpes simplex virus, human papillomavirus
syphilis, gonorrhea, chancroid, and chlamydia) and are themselves at risk for infection
with these pathogens, as well as others that carry serious consequences for immuno-
suppressed persons, including cytomegalovirus and human herpes virus 8 (also
known as KSHV). Therefore, all HIV-infected persons, including those receiving effec-
tive antiretroviral therapies, should be counseled to avoid behaviors associated with
the transmission of HIV and other infectious agents. Continued reinforcement that all
HIV-infected persons adhere to safe-sex practices is important. If an HIV-infected in-
jecting-drug user is unable or unwilling to refrain from using injection drugs, that
person should be counseled to avoid sharing injection equipment with others and to
use sterile, disposable needles and syringes for each injection.
SCIENTIFIC BACKGROUND
HIV Infection Leads to Progressive Immune System Damage in
Nearly All Infected Persons
Early efforts to synthesize a coherent model of the pathogenic consequences of HIV
infection were based on the presumption that few cells in infected persons harbor or
produce HIV and that virus replication is restricted during the period of clinical latency.
However, early virus detection methods were insensitive, and newer, more sensitive
tests have demonstrated that virus replication is active throughout the course of the
infection and proceeds at levels far higher than previously imagined. HIV replication
has been directly linked to the process of T cell destruction and depletion. In addition,
ongoing HIV replication in the face of an active but incompletely effective host antivi-
ral immune response is probably responsible for the secondary manifestations of HIV
disease, including wasting and dementia.
Beginning with the first cycles of virus replication within the newly infected host,
HIV infection results in the progressive destruction of the population of CD4+ T cells
that serve essential roles in the generation and maintenance of host immune re-
sponses (1–10 ). The target cell preference for HIV infection and depletion is
determined by the identity of the cell surface molecule, CD4, that is recognized by the
HIV envelope (Env) glycoprotein as the virus binds to and enters host cells to initiate
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the virus replication cycle (74 ). Additional cell surface molecules that normally func-
tion as receptors for chemokines have recently been identified as essential
co-receptors required for the process of HIV entry into target cells (75 ). Macrophages
and their counterparts within the central nervous system, the microglial cells, also
express cell surface CD4 and provide targets for HIV infection. As macrophages are
more resistant to the cytopathic consequences of HIV infection than are CD4+ T cells
and are widely distributed throughout the body, they may play critical roles in persist-
ence of HIV infection by providing reservoirs of chronically infected cells.
Although most of the immunologic and virologic assessments of HIV-infected per-
sons have focused on studies of peripheral blood lymphocytes, these cells represent
only approximately 2% of the total lymphocyte population in the body. The impor-
tance of the lymphoid organs, which contain the majority of CD4+ T cells, has been
highlighted by the finding that the concentrations of virus and percentages of HIV-
infected CD4+ T cells are substantially higher in lymph nodes (where immune re-
sponses are generated and where activated and proliferating CD4+ T cells that are
highly susceptible to HIV infection are prevalent) than in peripheral blood (3,4,48 ).
Thus, although the depletion of CD4+ T cells after HIV infection is most readily re-
vealed by sampling peripheral blood, damage to the immune system is exacted in
lymphoid organs throughout the body (3,4 ). For as yet unidentified reasons, gradual
destruction of normal lymph node architecture occurs with time, which probably com-
promises the ability of an HIV-infected person to generate effective immune
responses and replace CD4+ T cells already lost to HIV infection through the expan-
sion of mature T cell populations in peripheral lymphoid tissues. The thymus is also
an early target of HIV infection and damage, thereby limiting the continuation of effec-
tive T cell production even in younger persons in whom thymic production of CD4+
T cells is active (76,77 ). Thus, in both adults and children, HIV infection compromises
both of the potential sources of T cell production, so the rate of T cell replenishment
cannot continue indefinitely to match cell loss. Consequently, total CD4+ T cell num-
bers may decline inexorably in HIV-infected persons.
After initial infection, the pace at which immunodeficiency develops and the atten-
dant susceptibility to OIs which arise are associated with the rate of decline of CD4+ T
cell counts (11,26,27 ). The rate at which CD4+ T cell counts decline differs consider-
ably from person to person and is not constant throughout all stages of the infection.
Acceleration in the rate of decline of CD4+ T cells heralds the progression of disease.
The virologic and immunologic events that occur around this time are poorly under-
stood, but increasing rates of HIV replication, the emergence of viruses demonstrating
increased cytopathic effects for CD4+ T cells, and declining host cell-mediated anti-HIV
immune responses are often seen (12,78 ). For as yet unknown reasons, host compen-
satory responses that preserve the homeostasis of total T cell levels (CD4+ plus CD8+
T cells) appear to break down in HIV-infected persons approximately 1–2 years before
the development of AIDS, resulting in net loss of total T cells in the peripheral blood,
and signaling immune system collapse (79 ).
Although the progression of HIV disease is most readily gauged by declining CD4+
T cell numbers, evidence indicates that the sequential loss of specific types of immune
responses also occurs (80–82 ). Memory CD4+ T cells are known to be preferential
targets for HIV infection, and early loss of CD4+ memory T cell responses is observed
in HIV-infected persons, even before there are substantial decreases in total CD4+ T
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cell numbers (80,81 ). With time, gradual attrition of antigen-specific CD4+ T cell-
dependent immune recognition may limit the repertoire of immune responses that
can be mounted effectively and so predispose the host to infection with opportunistic
pathogens (82 ).
HIV Replication Rates in Infected Persons Can Be Accurately
Gauged By Measurement of Plasma HIV Concentrations
Until recently, methods for monitoring HIV replication (commonly referred to as
viral load) in infected persons were either hampered by poor sensitivity and repro-
ducibility or were so technically laborious that they could not be adapted for routine
clinical practice. However, new techniques for sensitive detection and accurate quan-
tification of HIV RNA levels in the plasma of infected persons provide extremely useful
measures of active virus replication (1,2,19,20,37,41–43 ). HIV RNA in plasma is con-
tained within circulating virus particles or virions, with each virion containing two
copies of HIV genomic RNA. Plasma HIV RNA concentrations can be quantified by
either target amplification methods (e.g., quantitative RT polymerase chain reaction
[RT-PCR], Amplicor HIV Monitor  assay, Roche Molecular Systems; or nucleic acid
sequence-based amplification, [NASBA®], NucliSens  HIV-1 QT assay, Organon
Teknika) or signal amplification methods (e.g., branched DNA [bDNA], Quantiplex
HIV RNA bDNA assay, Chiron Diagnostics) (42,43 ). The bDNA signal amplification
method (41) amplifies the signal obtained from a captured HIV RNA target by using
sequential oligonucleotide hybridization steps, whereas the RT-PCR and NASBA® as-
says use enzymatic methods to amplify the target HIV RNA into measurable amounts
of nucleic acid product (41–43 ) . Target HIV RNA sequences are quantitated by com-
parison with internal or external reference standards, depending upon the assay used.
Versions of both types of assays are now commercially available, and the Amplicor
assay was recently approved by the Food and Drug Administration for assessment for
risk of disease progression and monitoring of antiretroviral therapy in HIV-infected
persons. Target amplification assays are more sensitive (400 copies HIV RNA/mL
plasma) than the first generation bDNA assay (10,000 copies HIV plasma), but the sen-
sitivity of the bDNA assay has recently been improved (500 copies HIV RNA/mL
plasma). More sensitive versions of each of these assays are currently in development
(detection limits 20–100 copies/mL) and will likely be commercially available in the
future.
All of the commercially available assays can accurately quantitate plasma HIV RNA
levels across a wide range of concentrations (so-called dynamic range). Although the
results of the three assays (i.e., the RT-PCR, NASBA®, and bDNA) are strongly corre-
lated, the absolute values of HIV RNA measured in the same plasma sample using two
different assays can differ by twofold or more (44–46 ). Until a common standard is
available that can be used to normalize values obtained with different assay methods,
it is advisable to choose one assay method consistently when HIV RNA levels in in-
fected persons are monitored for use as a guide in making therapeutic decisions.
The performance characteristics and recommended collection methods for the in-
dividual HIV RNA assays are provided (Table). For reliable results, it is essential that
the recommended procedures be followed for collection and processing of blood to
prepare plasma for HIV RNA measurements. Different plasma HIV RNA assays require
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different plasma volumes (an important consideration in infants and in young chil-
dren). These assays are best performed on plasma specimens prepared from blood
obtained in collection tubes containing specific anticoagulants (e.g., ethy-
lenediaminetetraacetic acid [EDTA] or acid-citrate-dextran [ACD]) (Table) (44–46 ).
Quantitative measurement of plasma HIV RNA levels can be expressed in two
ways: a) the number of copies/mL of HIV RNA and b) the logarithm (to the base 10) of
the number of copies/mL of HIV RNA. In clinically stable, HIV-infected adults, results
obtained by using commercially available plasma HIV RNA assays can vary by ap-
proximately threefold (0.5 log10) in either direction on repeated measurements
obtained within the same day or on different days (35,36 ). Factors influencing the
variation seen in plasma HIV RNA assays include biological fluctuations and those
introduced by the performance characteristics of the particular assay (35,36,44–46 ).
Variability of current plasma HIV RNA assays is greater toward their lower limits of
detection and consequently changes greater than 0.5 log10 HIV RNA copies can be
seen near the assay detection limits without changes in clinical status (35 ). Differ-
ences greater than 0.5 log10 copies on repeated measures of plasma HIV RNA likely
reflect biologically and clinically relevant changes. Increased variance toward the limit
of assay detection presents an important consideration as the recommended target of
suppression of HIV replication by antiretroviral therapy is now defined as being HIV
RNA levels below the detection limit of plasma HIV RNA assays. Immune system acti-
vation (by immunizations or intercurrent infections) can lead to increased numbers of
activated CD4+ T cells, and thereby result in increased levels of HIV replication (re-
flected by significant elevations of plasma HIV RNA levels from their baseline values)
that may persist for as long as the inciting stimulus remains (32–34 ). Therefore, meas-
urements obtained surrounding these events may not reflect a patient’s actual
steady-state level of plasma HIV RNA. Unlike CD4+ T cell count determinations,
plasma HIV RNA levels do not exhibit diurnal variation (26,36 ). Within the large dy-
namic range of plasma HIV RNA levels that can be measured (varying over several
log10 copies), the observed level of assay variance is low (Table). Measurement of two
samples at baseline in clinically stable patients has been recommended as a way of
reducing the impact of the variability of plasma HIV RNA assays (19 ), and recent data
support this approach (22 ).
The level of viremia, as measured by the amount of HIV RNA in the plasma, accu-
rately reflects the extent of virus replication in an infected person (1,2,20,37 ).
Although the lymphoid tissues (e.g., lymph nodes and other compartments of the
reticuloendothelial system) provide the major sites of active virus production in HIV-
infected persons, virus produced in these tissues is released into the peripheral
circulation where it can be readily sampled (3,4,48 ). Thus, plasma HIV RNA concentra-
tions reflect the level of active virus replication throughout the body, although it is not
known whether specific compartments (e.g., the central nervous system [CNS]) repre-
sent sites of infection that are not in direct communication with the peripheral pool of
virus.
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The Magnitude of HIV Replication in Infected Persons
Determines Their Rate of Disease Progression
Plasma HIV RNA can be detected in virtually all HIV-infected persons although its
concentration can vary widely depending on the stage of the infection (Figure 1) and
on incompletely understood aspects of the host–virus interactions. During primary
infection in adults when there are numerous target cells susceptible to HIV infection
without a countervailing host immune response, concentrations of plasma HIV RNA
can exceed 107 copies/mL (83 ). HIV disseminates widely throughout the body during
this period, and many newly infected persons display symptoms of an acute viral ill-
ness, including fever, fatigue, pharyngitis, rash, myalgias, and headache (84–86 ).
Coincident with the emergence of antiviral immune responses, concentrations of
plasma HIV RNA decline precipitously (by 2 to 3 log10 copies or more). After a period
of fluctuation, often lasting 6 months or more, plasma HIV RNA levels usually stabilize
around a so-called set-point (5,6,10,27,31,86 ). The determinants of this set-point are
incompletely understood but probably include the number of susceptible CD4+ T cells
and macrophages available for infection, the degree of immune activation, and the
tropism and replicative vigor (fitness) of the prevailing HIV strain at various times fol-
lowing the initial infection, as well as the effectiveness of the host anti-HIV immune
response. In contrast to adults, HIV-infected infants often have very high levels of
plasma HIV RNA that decline slowly with time and do not reach set-point levels until
more than a year after infection (14–18 ).
Different infected persons display different steady-state levels of HIV replication.
When populations of HIV-infected adults are studied in a cross-sectional manner, an
inverse correlation between plasma HIV RNA levels and CD4+ T cell counts is seen
(87,88 ). However, at any given CD4+ T cell count, plasma HIV RNA concentrations
show wide interindividual variation (87,88 ). In established HIV infection, persistent
concentrations of plasma HIV RNA range from <200 copies/mL in extraordinary per-
sons who have apparently nonprogressive HIV infection to >106 copies/mL in persons
who are in the advanced stages of immunodeficiency or are at risk for very rapid dis-
ease progression. In most HIV-infected and untreated adults, set-point plasma HIV
RNA levels range between 103 and 105 copies/mL. Persons who have higher steady-
state set-point levels of plasma HIV RNA generally lose CD4+ T cells more quickly,
progress to AIDS more rapidly, and die sooner than those with lower HIV RNA set-
point levels (5–7,10,27 ) (Figures 2–4). Once established, set-point HIV RNA levels can
remain fairly constant for months to years. However, studies of populations of HIV-in-
fected persons suggest a gradual trend toward increasing HIV RNA concentrations
with time after infection (10 ). Within individual HIV-infected persons, rates of increase
of plasma HIV RNA levels can change gradually, abruptly, or hardly at all (10 ). Pro-
gressively increasing plasma HIV RNA concentrations can signal the development of
advancing immunodeficiency, regardless of the initial set-point value (10,75 ).
Plasma HIV RNA levels provide more powerful predictors of risk of progression to
AIDS and death than do CD4+ T cell levels; however, the combined measurement of
the two values provides an even more accurate method to assess the prognosis of
HIV-infected persons (27 ). The relationship between baseline HIV RNA levels meas-
ured in a large cohort of HIV-infected adults and their subsequent rate of CD4+ T cell
decline is shown (Figure 3) (27 ). Progressive loss of CD4+ T cells is observed in all
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strata of baseline plasma HIV RNA concentrations, but substantially more rapid rates
of decline are seen in persons who have higher baseline levels of plasma HIV RNA
(Figure 3) (27 ) . Likewise, a clear gradient in risk for disease progression and death is
seen with increasing baseline plasma HIV RNA levels (5,6,10,27 ) (Figures 2 and 4).
HIV Replicates Actively at All Stages of the Infection
The steady-state level of HIV RNA in the plasma is a function of the rates of produc-
tion and clearance (i.e., the turnover) of the virus in circulation (1,2,20,21,37 ). Effective
antiretroviral therapy perturbs this steady state and allows an assessment of the ki-
netic events that underlie it. Thus, virus clearance, the magnitude of virus production,
and the longevity of virus-producing cells can all be measured. Recent studies in
which measurements of virus and infected-cell turnover were analyzed in this way in
persons who had moderate to advanced HIV disease have demonstrated that a very
dynamic process of virus production and clearance underlies the seemingly static
steady-state level of HIV virions in the plasma (1,2,20,21,37 ).
Within 2 weeks of initiation of potent antiretroviral therapy, plasma HIV RNA levels
usually fall to approximately 1% of their initial values (20,37 ) (Figure 5). The slope of
this initial decline reflects the clearance of virus from the circulation and the longevity
of recently infected CD4+ T cells and is remarkably constant among different persons
(1,2,20,37 ). The half-life of virions in circulation is exceedingly short—less than 6
hours. Thus, on average, half of the population of plasma virions turns over every 6
hours or less. Given such a rapid rate of virus clearance, it is estimated that 109 to 1010
(or more) virions must be produced each day to maintain the steady-state plasma HIV
RNA levels typically found in persons who have moderate to advanced HIV disease
(20 ). When new rounds of virus replication are blocked by potent antiretroviral drugs,
virus production from the majority of infected cells (approximately 99%) continues for
only a short period, averaging approximately 2 days (1,2,20,37 ). HIV-infected CD4+ T
cells are lost, presumably as the result of direct cytopathic effects of virus infection,
with an average half-life of an infected cell being approximately 1.25 days (20 ). The
estimated generation time of HIV (the time from release of a virion until it infects an-
other cell and results in the release of a new generation of virions) is approximately
2.5 days, which implies that the virus is replicating at a rate of approximately 140 or
more cycles per year in an infected person (20,21 ). Thus, at the median period be-
tween initial infection and the diagnosis of AIDS, each virus genome present in an
HIV-infected person is removed by more than a thousand generations from the virus
that initiated the infection.
After the initial rapid decline in plasma HIV RNA levels following initiation of potent
antiretroviral therapy, a slower decay of the remaining 1% of initial plasma HIV RNA
levels is observed (37 ) (Figure 5). The length of this second phase of virus decay dif-
fers among different persons, lasting approximately 8–28 days. Most of the residual
viremia is thought to arise from infected macrophages that are lost over an average
half-life of about 2 weeks, whereas the remainder is produced following activation of
latently infected CD4+ T cells that decay with an average half-life of about 8 days.
Within 8 weeks of initiation of potent antiretroviral therapy (in previously untreated
patients), plasma HIV RNA levels commonly fall below the level of detection of even
the most sensitive plasma HIV RNA assays available (sensitivity of 25 copies HIV
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RNA/mL), indicating that new rounds of HIV infection are profoundly suppressed
(Figure 5) (37 ). Fortunately, this level of suppression of HIV replication appears to
have been maintained for more than 16 months in most patients who adhere to effec-
tive combination antiretroviral drug regimens (39 ). However, even this marked
pharmacologic interference of HIV replication has not yet been reported to eradicate
an established infection. Those rare persons who have been studied after having
stopped effective combination antiretroviral therapy following months with undetect-
able levels of plasma HIV RNA have all shown rapid rebounds in HIV replication.
Furthermore, infectious HIV can still be isolated from CD4+ T cells obtained from an-
tiretroviral treated persons whose plasma HIV RNA levels have been suppressed to
undetectable levels (<50 copies/mL) for 2 years or more (49,50 ). Viruses recovered
from these persons were demonstrated to be sensitive to the antiretroviral drugs
used, indicating that a reservoir of latently infected resting CD4+ T cells exists that can
maintain HIV infection for prolonged periods even when new cycles of virus replica-
tion are blocked. It is not known whether additional reservoirs of residual HIV infection
exist in infected persons that can permit persistence of HIV infection despite profound
inhibition of virus replication by effective combination antiretroviral therapies
(37,47,48 ). HIV infection within the CNS represents an additional potential sanctuary
for virus persistence, as many of the antiretroviral drugs now available do not effi-
ciently cross the blood-brain barrier.
Active HIV Replication Continuously Generates Viral Variants
That are Resistant to Antiretroviral Drugs
HIV replication depends on a virally encoded enzyme, RT (an RNA-dependent DNA
polymerase) that copies the single-stranded viral RNA genome into a double-stranded
DNA in an essential step in the virus life cycle (21 ). Unlike cellular DNA polymerases
used to copy host cell chromosomal DNA during the course of cell replication, RT
lacks a 3’ exonuclease activity that serves a “proofreading” function to repair errors
made during transcription of the HIV genome. As a result, the HIV RT is an “error-
prone” enzyme, making frequent errors while copying the RNA into DNA and giving
rise to numerous mutations in the progeny virus genomes produced from infected
cells. Estimates of the mutation rate of HIV RT predict that an average of one mutation
is introduced in every one to three HIV genomes copied (21,89 ). Additional variation
is introduced into the replicating population of HIV variants as a result of genetic re-
combination that occurs during the process of reverse transcription via
template-switching between the two HIV RNA molecules that are included in each
virus particle (21,90 ). Many mutations introduced into the HIV genome during the
process of reverse transcription will compromise or abolish the infectivity of the virus;
however, other mutations are compatible with virus infectivity. In HIV-infected per-
sons, the actual frequency with which different genetic variants of HIV are seen is a
function of their replicative vigor (fitness) and the nature of the selective pressures
that may be acting on the existing swarm of genetic variants present (21 ). Important
selective pressures that may exist in HIV-infected persons include their anti-HIV im-
mune responses, the availability of host cells that are susceptible to virus infection in
different tissues, and the use of antiretroviral drug treatments.
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The rate of appearance of genetic variants of HIV within infected persons is a func-
tion of the number of cycles of virus replication that occurs during a person’s infection
(20,21 ). That numerous rounds of HIV replication are occurring daily in infected per-
sons provides the opportunity to generate large numbers of variant viruses, including
those that display diminished sensitivity to antiretroviral drugs. A mutation is prob-
ably introduced into every position of the HIV genome many times each day within an
infected person, and the resulting HIV variants may accumulate within the resident
virus population with successive cycles of virus replication (21 ). As a result of the
great genetic diversity of the resident population of HIV, viruses harboring mutations
that confer resistance to a given antiretroviral drug, and perhaps multiple antiretrovi-
ral drugs, are likely to be present in HIV-infected persons before antiretroviral therapy
is initiated (21 ). Indeed, mutations that confer resistance to nucleoside analog RT in-
hibitors, NNRTIs, and PIs have been identified in HIV-infected persons who have never
been treated with antiretroviral drugs (61,91,92 ). Once drug therapy is initiated, the
pre-existing population of drug-resistant viruses can rapidly predominate. For drugs
such as 3TC and nevirapine (and other NNRTIs), a single nucleotide change in the HIV
RT gene can confer 100- to 1,000-fold reductions in drug susceptibility (1,61,93–95 ).
Although these agents may be potent inhibitors of HIV replication, the antiretroviral
activity of these drugs when used alone is largely reversed within 4 weeks of initiation
of therapy due to the rapid outgrowth of drug-resistant variants (1,61,93–95 ). The ra-
pidity with which drug-resistant variants emerge in this setting is consistent with the
existence of drug-resistant subpopulations of HIV within infected patients before to
the initiation of treatment (21,61 ). Because treatment with many of the available an-
tiretroviral drugs selects for HIV variants that harbor the same or related mutations,
specific treatments can select for the outgrowth of HIV variants that are resistant to
drugs with which the patient has not been treated (referred to as cross-resistance)
(96,97 ).
Drug-resistant viruses that emerge during drug therapy are predicted to replicate
less well (are less fit) than their wild-type counterparts and are expected to attain
lower steady-state levels of viral load than are present before the initiation of therapy
(21 ). Evidence for such decreased fitness of drug-resistant viruses has been gleaned
from studies of protease-inhibitor–treated or 3TC-treated patients, but this effect has
not been apparent in NNRTI-treated patients (e.g., nevirapine or delavirdine) (1,61 ).
Depending on its relative fitness, the drug-resistant variant can persist at appreciable
levels even after the antiretroviral therapy that selected for its outgrowth is with-
drawn. HIV variants resistant to nevirapine can persist for more than a year after
withdrawal of nevirapine treatment (61 ). Zidovudine-resistant HIV variants and vari-
ants resistant to both zidovudine and nevirapine have also been shown to persist in
infected persons and to replicate well enough to be transmitted from one person to
another (98 ). Because HIV variants that are resistant to PIs often appear to be less fit
than drug-sensitive viruses, their prevalence in patients who develop PI resistance
may decline after withdrawal of the drug. However, although such variants may de-
cline after drug withdrawal, they also may persist in patients at higher levels than their
original levels and can be rapidly selected for should the same antiretroviral agent (or
a PI demonstrating cross-resistance) be used again (97 ).
The definition of mutations associated with resistance to specific antiretroviral
drugs and the advent of genetic methods to detect drug-resistant variants in treated
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patients have raised the possibility of screening HIV-infected patients for the presence
of HIV variants as a tool to guide therapeutic decisions (92,99 ). However, this ap-
proach must be considered experimental and may prove very difficult to implement
because of the complex patterns of mutations that increase resistance to some an-
tiretroviral agents. Furthermore, the prevalence of clinically important populations of
drug-resistant variants in many HIV-infected persons is likely to be below the level of
detection of the available assays, thus potentially creating falsely optimistic predic-
tions of drug efficacy (21,61 ).
Combination Antiretroviral Therapy That Suppresses HIV
Replication to Undetectable Levels Can Delay or Prevent the
Emergence of Drug-Resistant Viral Variants
Current strategies for antiretroviral therapy are much more effective than those
previously available, and the efficacy of these approaches confirms predictions
emerging from fundamental studies of the biology of HIV infection. Several important
principles have emerged from these studies that can be used to guide the application
of antiretroviral therapies in clinical practice:
• The likelihood that HIV variants that are resistant to individual drugs (and possi-
bly combinations of drugs) are already present in untreated patients must be
appreciated.
• The likelihood that drug-resistant variants are already present in an HIV-infected
person decreases as the number of noncross-resistant antiretroviral drugs used
in combination is increased.
• The prevalence in untreated patients of HIV variants already resistant to an-
tiretroviral agents that require multiple mutations in the virus target gene to
confer high-level drug resistance is also expected to be lower as the number of
required mutations increases. For example, high-level resistance to PIs (e.g., rito-
navir and indinavir) requires the presence of multiple mutations in the HIV
protease gene; some of these mutations affect the actual antiviral action of the
drug, whereas others represent compensatory mutations that act to increase the
fitness of the drug-resistant HIV variants (96,97,100 ). The prevalence of HIV vari-
ants that already harbor all of the mutations required for high-level resistance to
these drugs is expected to be low in untreated patients.
• Antiretroviral drugs that select for partially disabled (less fit) viruses may benefit
the host by decreasing the amount of virus replication (and consequent damage)
that occurs even after drug-resistant mutants have overgrown drug-sensitive vi-
ruses.
• Incomplete suppression of HIV replication (as indicated by the continued pres-
ence of detectable levels of plasma HIV RNA) will afford the opportunity for
continued accumulation of mutations that confer high-level drug resistance, and
thereby facilitate the eventual outgrowth of the resistant virus population during
continued therapy (23,39 ). The more effectively new cycles of HIV infection are
suppressed, the fewer opportunities are provided for the accumulation of new
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mutations that permit the emergence of drug-resistant variants (97,100 ). Thus,
initiation and maintenance of therapy with optimal doses of combinations of po-
tent antiretroviral drugs with the intent of suppressing HIV replication to levels
below the detection limit of sensitive plasma HIV RNA assays provide the most
promising strategy to forestall (or prevent) the emergence of drug-resistant vi-
ruses and achieve maximum protection from HIV-induced immune system
damage.
Antiretroviral Therapy-Induced Inhibition of HIV Replication
Predicts Clinical Benefit
As active HIV replication is directly linked to the progressive depletion of CD4+ T
cell populations, reduction in levels of virus replication by antiretroviral drug therapy
is predicted to correlate with the clinical benefits observed in treated patients. Data
from an increasing number of clinical trials of antiretroviral agents provide strong sup-
port for this prediction and indicate that greater clinical benefit is obtained from more
profound suppression of HIV replication (9,13,23,38–40,56 ). For example, virologic
analyses from ACTG 175 (a study of zidovudine or didanosine monotherapy com-
pared with combination therapy with zidovudine plus either didanosine or zalcitabine)
indicate that a reduction in plasma HIV RNA levels to 1.0 log below baseline at 56
weeks after initiation of therapy was associated with a 90% reduction in risk of pro-
gression of clinical disease (13 ). In a pooled analysis of seven different ACTG studies,
durable suppression of plasma HIV RNA levels to <5,000 copies of HIV RNA/mL be-
tween 1 and 2 years after initiation of treatment was associated with an average
increase in CD4+ T cell levels of approximately 90 cells/mm3 (24 ). Patients whose
plasma HIV RNA levels failed to be stably suppressed to <5,000 copies/mL showed
progressive decline in CD4+ T cell counts during the same period (24 ).
Decreases in plasma HIV RNA levels induced by antiretroviral therapy provide bet-
ter indicators of clinical benefit than CD4+ T cell responses (9,13,24 ). Furthermore, in
patients who have advanced HIV disease, clinical benefit correlates with treatment-
induced decreases in plasma HIV RNA levels, even when CD4+ T cell increases are not
seen. The failure to observe CD4+ T cell increases in some treated patients despite
suppression of HIV replication may reflect irreversible damage to the regenerative ca-
pacity of the immune system in the later stages of HIV disease.
The most extensive data on the relationship between the magnitude of suppres-
sion of HIV replication induced by antiretroviral therapy and the degree of improved
clinical outcome were generated during studies of nucleoside analog RT inhibitors
used alone or in combination (9,13,24 ). These treatments yield less profound and less
durable suppression of HIV replication than currently available combination therapy
regimens that include potent PIs (and that are able to suppress HIV replication to lev-
els below the detection limits of plasma HIV RNA assays) (23,37,39 ). Thus, it is likely
that the relationship between suppression of HIV replication and clinical benefit will
become even more apparent as experience with potent combination therapies accu-
mulates.
Repair of immune system function may be incomplete following effective inhibi-
tion of continuing HIV replication and damage by antiretroviral drug therapy.
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As discussed in the preceding principles, disease progression in HIV-infected pa-
tients results from active virus replication that inflicts chronic damage upon the
function of the immune system and its structural elements, the lymphoid tissues. Be-
cause of the clonal nature of the antigen-specific immune response, in the absence of
generation of immunocompetent CD4+ T cells from immature progenitor cells, it is
likely that T cell responses may not be regained once lost, even if new rounds of HIV
infection can be stopped by effective antiretroviral therapy (80,82,101 ). Similarly, it is
not known if the damaged architecture of the lymphoid organs seen in persons with
moderate to advanced HIV disease can be repaired following antiretroviral drug ther-
apy. Should the residual proliferative potential of CD4+ and CD8+ T cells decline with
increased duration of HIV infection and the magnitude of the cumulative loss and re-
generation of lymphocyte populations, late introduction of antiretroviral therapy may
have limited ability to reconstitute levels of functional lymphocytes. Thus, it is be-
lieved that the initiation of antiretroviral therapy before extensive immune system
damage has occurred will be more effective in preserving and improving the ability of
the HIV-infected person to mount protective immune responses.
Few reliable methods are now available to assess the integrity of immune re-
sponses in humans. However, the application of specific methods to the study of
immune responses in HIV-infected patients before and after initiation of antiretroviral
therapy indicates that immunologic recovery is incomplete even when HIV replication
falls to undetectable levels. CD4+ T cell levels do not return to the normal range in
most antiretroviral drug-treated patients, and the extent of CD4+ T cell increase is typi-
cally more limited when therapy is started in the later stages of HIV disease (82 ).
Recent evidence indicates that the repertoire of antigen-specific CD4+ T cells becomes
progressively constricted with declining T cell numbers (82 ). In persons who have
evidence of a restricted T cell repertoire, antiretroviral therapy can increase total CD4+
T cell numbers but fails to increase the diversity of antigen recognition ability (82 ). It
is not yet known if expansion of a constricted CD4+ T cell repertoire of antigen recog-
nition might be seen with longer-term follow-up of such persons.
Reports of OIs occurring in antiretroviral-treated patients at substantially higher
CD4+ T cell counts than those typically associated with susceptibility to the specific
opportunistic infections raise the concern that restoration of protective immune re-
sponses may be incomplete, even when effective suppression of continuing HIV
replication is achieved (102 ). However, other reports describe instances in which the
clinical symptoms or signs of preexisting OIs were ameliorated (103–105 ), or in which
new inflammatory responses to preexisting, but subclinical, OIs became manifest fol-
lowing initiation of effective combination antiretroviral therapy (106,107 ). These
observations indicate that some improvement in immune function may be possible,
even in patients who have advanced HIV disease, if sufficient numbers of pathogen-
specific CD4+ T cells are still present when effective antiretroviral therapy is begun.
The extent to which antiretroviral therapy can restore immune function when initiated
in persons at varying stages of HIV disease is currently unknown but represents an
essential question for future research.
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RT-PCR¶ 4 x 102–105.2 <0.15–0.33 ACD/EDTA**
bDNA†† 5 x 102–1.6 x 106 0.08–0.2 EDTA**
NASBA®§§ 4 x 102–4 x 107 0.13–0.23 ACD/EDTA/HEP**
Appendices
 *More sensitive versions of each of these assays (detection limits 20–100 HIV RNA copies/mL)
are currently in development and will likely be commercially available in the future.
†Higher values can be measured with dilution of the specimen into the linear dynamic range
for each assay.
§Ranges are representative of those obtained in comparative analyses of plasma HIV RNA
assays (44–46 ). Plasma HIV RNA assays tend to be more variable at or near the limit of
quantitation. Thus, the significance of changes in HIV RNA levels at the lowest levels of
quantitation for a given assay should be evaluated in light of this increased variability.
¶Amplicor HIV Monitor  assay (Roche Molecular Systems, Alameda, CA).
**ACD = acid citrate dextran (citrate; yellow-top tube); EDTA = ethylenediaminetetraacetic acid
(purple-top tube); HEP = heparin (green-top tube).
††Quantiplex  HIV RNA bDNA assay (Chiron Diagnostics, Emeryville, CA).
§§NucliSens  HIV-1 QT assay (Organon Teknika, Boxtel, The Netherlands).































































FIGURE 1. Generalized time course of HIV infection and disease
Three different patterns of disease progression: rapid, intermediate, and late progression.
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Kaplan-Meier curves showing AIDS-free survival by plasma HIV RNA category among groups
of persons with different baseline CD4+ T cell counts who participated in the Multicenter AIDS
Cohort Study (MACS) (27). The five categories of baseline HIV RNA levels were (I) ≤500;
(II) 501–3,000; (III) 3,001–10,000; (IV) 10,001–30,000; and (V) >30,000 copies/mL. Within each
CD4+ T cell category, baseline HIV RNA concentration provided significant discrimination of
AIDS-free times (p<0.001) and survival times (27). In the lowest CD4+ T cell category (<200
cells/mm3), there were too few participants with HIV RNA concentrations of ≤10,000 copies/mL
to provide reliable estimates for RNA categories I-III. In the next lowest CD4+ T cell categories
(201–350 and 351–500 cells/mm3), there were too few participants with HIV RNA concentrations
of ≤500 copies/mL (category I) to provide reliable estimates. Plasma HIV RNA concentrations








































































































FIGURE 2. AIDS-free survival by baseline plasma HIV RNA and CD4+ T cell levels
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FIGURE 3. Association between rates of decline of CD4+ T cell counts and baseline
plasma HIV RNA level
*Confidence intervals.
The relationship between baseline HIV-1 RNA level and the subsequent rate of decline in CD4+
T cells seen in participants of the Multicenter AIDS Cohort Study (MACS) (27 ). The study
population was divided into five categories of plasma HIV-1 RNA defined by baseline concen-
trations of (I) ≤500; (II) 501–3,000; (III) 3,001–10,000; (IV) 10,001–30,000; and (V) >30,000
copies/mL. The estimated mean slope of decline in CD4+ T cells (number of cells lost per year)
and 95% CIs by plasma HIV-1 RNA category are shown. The estimated rates of decline in CD4+
T cell counts are substantially different for each of the five baseline HIV RNA categories and
show a monotonic relationship; i.e., the higher the baseline HIV RNA concentration, the greater
the rate of decline of CD4+ T cell count. Plasma HIV RNA concentrations were measured using
the Quantiplex  HIV RNA bDNA assay.




















































































































































































FIGURE 4. Probability of AIDS by baseline HIV RNA level and CD4+ T cell count
*Confidence interval.
A regression tree containing 14 distinct categories of risk of progression to AIDS defined among participants in the Multicenter AIDS
Cohort Study (MACS) (27). The risk of progression to AIDS can be assessed for many infected persons through the combined analysis
of their baseline HIV RNA levels and CD4+ T cell counts. The number of study participants in each group is indicated by “N.” AIDS risk


















































FIGURE 5. Rate of decline of plasma HIV RNA concentration after initiation of potent combination antiretroviral therapy
A representative time course of rate of decline in plasma HIV RNA concentration (in log10 copies of RNA/mL) following initiation of a
potent regimen of combination antiretroviral therapy (e.g., two nucleoside analog reverse transcriptase inhibitors [such as zidovudine
and lamivudine] plus a potent, bioavailable protease inhibitor [such as indinavir, nelfinavir, or ritonavir]). The first phase of decline is a
rapid, approximately 2 log10 (100-fold) fall in plasma HIV RNA concentrations. The slope of this first phase of decline in plasma RNA
levels is very similar between different persons initiating effective antiretroviral therapies. A second, more gradual phase of decline in
plasma HIV RNA levels is seen over subsequent weeks, the slope of which varies between different treated persons. Many effectively
treated persons will demonstrate declines in plasma RNA levels to below the limits of assay detection (500 copies RNA/mL) by
approximately 8 weeks after initiation of antiretroviral therapy, although some persons may take longer to demonstrate undetectable
virus. (37,39 ). When plasma HIV RNA levels fall below detection, the absolute nadir is unknown. However, plasma HIV RNA levels have
decreased below the detection limits of even more sensitive assays (sensitivity of 25 RNA copies/mL) in many effectively treated persons.
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Guidelines for the Use of Antiretroviral Agents in
HIV-Infected Adults and Adolescents*
Summary
With the development and FDA approval of an increasing number of an-
tiretroviral agents, decisions regarding the treatment of HIV-infected persons
have become complex; and the field continues to evolve rapidly. In 1996, the
Department of Health and Human Services and the Henry J. Kaiser Family Foun-
dation convened the Panel on Clinical Practices for the Treatment of HIV to
develop guidelines for the clinical management of HIV-infected persons. This
report includes the guidelines developed by the Panel regarding the use of labo-
ratory testing in initiating and managing antiretroviral therapy, considerations
for initiating therapy, whom to treat, what regimen of antiretroviral agents to
use, when to change the antiretroviral regimen, treatment of the acutely HIV-
infected person, special considerations in adolescents, and special considera-
tions in pregnant women. Viral load and CD4+ T cell testing should ideally be
performed twice before initiating or changing an antiretroviral treatment regi-
men. All patients who have advanced or symptomatic HIV disease should
receive aggressive antiretroviral therapy. Initiation of therapy in the asympto-
matic person is more complex and involves consideration of multiple virologic,
immunologic, and psychosocial factors. In general, persons who have <500
CD4+ T cells per mm
3
 should be offered therapy; however, the strength of the
recommendation to treat should be based on the patient’s willingness to accept
therapy as well as the prognosis for AIDS-free survival as determined by the HIV
RNA copy per mL of plasma and the CD4+ T cell count. Persons who have >500
CD4+ T cells per mm3 can be observed or can be offered therapy; again, risk of
progression to AIDS, as determined by HIV RNA viremia and CD4+ T cell count,
should guide the decision to treat. Once the decision to initiate antiretroviral
therapy has been made, treatment should be aggressive with the goal of maxi-
mal viral suppression. In general, a protease inhibitor and two non-nucleoside
reverse transcriptase inhibitors should be used initially. Other regimens may be
utilized but are considered less than optimal. Many factors, including reappear-
ance of previously undetectable HIV RNA, may indicate treatment failure.
Decisions to change therapy and decisions regarding new regimens must be
carefully considered; there are minimal clinical data to guide these decisions.
Patients with acute HIV infection should probably be administered aggressive
antiretroviral therapy; once initiated, duration of treatment is unknown and will
likely need to continue for several years, if not for life. Special considerations
apply to adolescents and pregnant women and are discussed in detail.
*Information included in these guidelines may not represent FDA approval or approved labeling
for the particular products or indications in question. Specifically, the terms “safe” and “ef-
fective” may not be synonymous with the FDA-defined legal standards for product approval.
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INTRODUCTION
These guidelines were developed by the Panel on Clinical Practices for Treatment
of HIV Infection, convened by the Department of Health and Human Services (DHHS)
and the Henry J. Kaiser Family Foundation. The guidelines contain recommendations
for the clinical use of antiretroviral agents in the treatment of adults and adolescents
(defined in Considerations for Antiretroviral Therapy in the HIV-Infected Adolescent)
who are infected with the human immunodeficiency virus (HIV). Guidance for the use
of antiretroviral treatment in pediatric HIV infection is not contained in this report.
Although the pathogenesis of HIV infection and the general virologic and immu-
nologic principles underlying the use of antiretroviral therapy are similar for all
HIV-infected persons, unique therapeutic and management considerations apply to
HIV-infected children. In recognition of these differences, a separate set of guidelines
will address pediatric-specific issues related to antiretroviral therapy.
These guidelines are intended for use by physicians and other health-care provid-
ers who use antiretroviral therapy to treat HIV-infected adults and adolescents. The
recommendations contained herein are presented in the context of and with reference
to the first section of this report, Principles of Therapy for HIV Infection, formulated by
the National Institutes of Health (NIH) Panel to Define Principles of Therapy of HIV
Infection. Together, these reports provide the pathogenesis-based rationale for thera-
peutic strategies as well as practical guidelines for implementing these strategies.
Although the guidelines represent the current state of knowledge regarding the use of
antiretroviral agents, this field of science is rapidly evolving, and the availability of
new agents or new clinical data regarding the use of existing agents will result in
changes in therapeutic options and preferences. The Antiretroviral Working Group, a
subgroup of the Panel, will meet several times a year to review new data; recommen-
dations for changes in this document would then be submitted to the Panel and
incorporated as appropriate. Copies of this document and all updates are available
from the CDC National AIDS Clearinghouse (1-800-458-5231) and are posted on the
Clearinghouse World-Wide Web site (http://www.cdcnac.org). In addition, copies and
updates also are available from the HIV/AIDS Treatment Information Service (1-800-
448-0440; Fax 301-519-6616; TTY 1-800-243-7012) and on the ATIS World-Wide Web
site (http://www.hivatis.org). Readers should consult these web sites regularly for up-
dates in the guidelines. These recommendations are not intended to substitute for the
judgment of a physician who is expert in caring for HIV-infected persons. When possi-
ble, the treatment of HIV-infected patients should be directed by a physician with
extensive experience in the care of these patients. When this is not possible, the phy-
sician treating the patient should have access to such expertise through consultations.
Each recommendation is accompanied by a rating that includes a letter and a Ro-
man numeral (Table 1), similar to the rating schemes described in previous guidelines
on the prophylaxis of opportunistic infections (OIs) issued by the U.S. Public Health
Service and the Infectious Diseases Society of America (1 ). The letter indicates the
strength of the recommendation based on the opinion of the Panel, and the Roman
numeral rating reflects the nature of the evidence for the recommendation (Table 1).
Thus, recommendations based on data from clinical trials with clinical endpoints are
differentiated from recommendations based on data derived from clinical trials with
laboratory endpoints (e.g., CD4+ T cell count or plasma HIV RNA levels); when clinical
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trial data are not available, recommendations are based on the opinions of experts
familiar with the relevant scientific literature. The majority of current clinical trial data
regarding the use of antiretroviral agents has been obtained in trials enrolling pre-
dominantly young to middle-aged males. Although current knowledge indicates that
women may differ from men in the absorption, metabolism, and clinical effects of
certain pharmacologic agents, clinical experience and data available to date do not
indicate any substantial sex differences that would modify these guidelines. However,
theoretical concerns exist, and the Panel urges continuation of the current efforts to
enroll more women in antiretroviral clinical trials so that the data needed to re-evalu-
ate this issue can be gathered expeditiously.
This report addresses the following issues: the use of testing for plasma HIV RNA
levels (viral load) and CD4+ T cell count; initiating therapy in established HIV infection;
initiating therapy in patients who have advanced-stage HIV disease; interruption of
antiretroviral therapy; changing therapy and available therapeutic options; the treat-
ment of acute HIV infection; antiretroviral therapy in adolescents; and antiretroviral
therapy in the pregnant woman.
USE OF TESTING FOR PLASMA HIV RNA LEVELS AND CD4+
T CELL COUNT IN GUIDING DECISIONS FOR THERAPY
Decisions regarding either initiating or changing antiretroviral therapy should be
guided by monitoring the laboratory parameters of both plasma HIV RNA (viral load)
and CD4+ T cell count and by assessing the clinical condition of the patient. Results of
these two laboratory tests provide the physician with important information about the
virologic and immunologic status of the patient and the risk of disease progression to
acquired immunodeficiency syndrome (AIDS) (see Principle 2 in the first section of
this report). HIV viral load testing has been approved by the U.S. Food and Drug Ad-
ministration (FDA) only for the RT-PCR assay (Roche) and only for determining disease
prognosis. However, data presented at an FDA Advisory Committee for the Division of
Antiviral Drug Products (July 14–15, 1997, Silver Spring, MD) provide further evidence
for the utility of viral RNA testing in monitoring therapeutic responses. Multiple analy-
ses of more than 5,000 patients who participated in approximately 18 trials with viral
load monitoring demonstrated a reproducible dose-response type association be-
tween decreases in plasma viremia and improved clinical outcome based on standard
endpoints of new AIDS-defining diagnoses and survival. This relationship was ob-
served over a range of patient baseline characteristics, including pretreatment plasma
RNA level, CD4+ T cell count, and prior drug experience. The consensus of the Panel
is that viral load testing is the essential parameter in decisions to initiate or change
antiretroviral therapies. Measurement of plasma HIV RNA levels (viral load), using
quantitative methods, should be performed at the time of diagnosis of HIV infection
and every 3–4 months thereafter in the untreated patient (AIII) (Table 2). CD4+ T cell
counts should be measured at the time of diagnosis and generally every 3–6 months
thereafter (AIII). These intervals between tests are merely recommendations, and
flexibility should be exercised according to the circumstances of the individual case.
Plasma HIV RNA levels also should be measured immediately prior to and again at 4–8
weeks after initiation of antiretroviral therapy (AIII). This second time point allows the
clinician to evaluate the initial effectiveness of therapy because in most patients, ad-
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herence to a regimen of potent antiretroviral agents should result in a large decrease
(~0.5 to 0.75 log10) in viral load by 4–8 weeks. The viral load should continue to decline
over the following weeks, and in most persons it becomes below detectable levels
(currently defined as <500 RNA copies/mL) by 12–16 weeks of therapy. The speed of
viral load decline and the movement toward undetectable are affected by the baseline
CD4+ T cell count, the initial viral load, potency of the regimen, adherence, prior expo-
sure to antiretroviral agents, and the presence of any OIs. These individual differences
must be considered when monitoring the effect of therapy. However, the absence of a
virologic response of the magnitude previously described (i.e., ~0.5 to 0.75 log10 by
4–8 weeks and undetectable by 12–16 weeks) should prompt the physician to reassess
patient adherence, rule out malabsorption, consider repeat RNA testing to document
lack of response, and/or consider a change in drug regimen. Once the patient is on
therapy, HIV RNA testing should be repeated every 3–4 months to evaluate the con-
tinuing effectiveness of therapy (AII). With optimal therapy, viral levels in plasma at 6
months should be undetectable (i.e., <500 copies of HIV RNA per mL of plasma) (2 ). If
HIV RNA remains above 500 copies/mL in plasma after 6 months of therapy, the
plasma HIV RNA test should be repeated to confirm the result, and a change in ther-
apy should be considered according to the guidelines provided in “Considerations for
Changing a Failing Regimen” (BIII). More sensitive viral load assays are in develop-
ment that can quantify HIV RNA down to approximately 50 copies/mL. Preliminary
data from clinical trials strongly suggest that lowering plasma HIV RNA to below 50
copies/mL is associated with a more complete and durable viral suppression, com-
pared with reducing HIV RNA to levels between 50–500 copies/mL. However, the
clinical significance of these findings is currently unclear.
When deciding whether to initiate therapy, the CD4+ T cell count and plasma HIV
RNA measurement ideally should be performed on two occasions to ensure accuracy
and consistency of measurement (BIII). However, in patients with advanced HIV dis-
ease, antiretroviral therapy should generally be initiated after the first viral load
measurement is obtained to prevent a potentially deleterious delay in treatment. Al-
though the requirement for two measurements of viral load may place a substantial
financial burden on patients or payers, two measurements of viral load should provide
the clinician with the best information for subsequent follow-up of the patient. Plasma
HIV RNA levels should not be measured during or within 4 weeks after successful
treatment of any intercurrent infection, resolution of symptomatic illness, or immuni-
zation (see Principle 2). Because differences exist among commercially available tests,
confirmatory plasma HIV RNA levels should be measured by the same laboratory us-
ing the same technique to ensure consistent results.
A substantial change in plasma viremia is considered to be a threefold or 0.5 log10
increase or decrease. A substantial decrease in CD4+ T cell count is a decrease of
>30% from baseline for absolute cell numbers and a decrease of >3% from baseline in
percentages of cells (3,4 ). Discordance between trends in CD4+ T cell numbers and
plasma HIV RNA levels can occur and was found in 20% of patients in one cohort
studied (5 ). Such discordance can complicate decisions regarding antiretroviral ther-
apy and may be due to several factors that affect plasma HIV RNA testing (see
Principle 2). Viral load and trends in viral load are considered to be more informative
for guiding decisions regarding antiretroviral therapy than are CD4+ T cell counts; ex-
ceptions to this rule do occur, however (see Considerations for Changing a Failing
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Regimen); when changes in viral loads and CD4+ T cell counts are discordant, expert
consultation should be considered.
ESTABLISHED HIV INFECTION
Patients who have established HIV infection are considered in two arbitrarily de-
fined clinical categories: 1) asymptomatic infection or 2) symptomatic disease (e.g.,
wasting, thrush, or unexplained fever for ≥2 weeks), including AIDS, defined accord-
ing to the 1993 CDC classification system (6 ). All patients in the second category
should be offered antiretroviral therapy. Considerations for initiating antiretroviral
therapy in the first category of patients (i.e., patients who are asymptomatic) are com-
plex and are discussed separately in the following section. However, before initiating
therapy in any patient, the following evaluation should be performed:
• Complete history and physical (AII)
• Complete blood count, chemistry profile (AII)
• CD4+ T cell count (AI)
• Plasma HIV RNA measurement (AI)
Additional evaluation should include routine tests pertinent to the prevention of
OIs, if not already performed (i.e., VDRL, tuberculin skin test, toxoplasma IgG serol-
ogy, and gynecologic exam with Pap smear), and other tests as clinically indicated
(e.g., chest radiograph, hepatitis C virus [HCV] serology, ophthalmologic exam) (AII).
Hepatitis B virus (HBV) serology is indicated for a patient who is a candidate for the
hepatitis B vaccine or who has abnormal liver function tests (AII); cytomegalovirus
(CMV) serology may be useful in certain persons, as discussed in 1997 USPHS/IDSA
Guidelines for the Prevention of Opportunistic Infections in Persons Infected With the
Human Immunodeficiency Virus (1 ) (BIII).
Considerations for Initiating Therapy in the Patient Who Has
Asymptomatic HIV Infection
It has been demonstrated that antiretroviral therapy provides clinical benefit in HIV-
infected persons who have advanced HIV disease and immunosuppression (7–11).
Although there is theoretical benefit to treating patients who have CD4+ T cells >500
cells/mm3 (see Principle 3), no long-term clinical benefit of treatment has yet been
demonstrated. A major dilemma confronting patients and practitioners is that the an-
tiretroviral regimens currently available that have the greatest potency in terms of
viral suppression and CD4+ T cell preservation are medically complex, are associated
with several specific side effects and drug interactions, and pose a substantial chal-
lenge for adherence. Thus, decisions regarding treatment of asymptomatic,
chronically infected persons must balance a number of competing factors that influ-
ence risk and benefit.
The physician and the asymptomatic patient must consider multiple risks and
benefits in deciding when to initiate therapy (Table 3) (see Principle 3). Several factors
influence the decision to initiate early therapy: the real or potential goal of maximally
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suppressing viral replication; preserving immune function; prolonging health and life;
decreasing the risk of drug resistance due to early suppression of viral replication with
potent therapy; and decreasing drug toxicity by treating the healthier patient. Factors
weighing against early treatment in the asymptomatic stable patient include the fol-
lowing: the potential adverse effects of the drugs on quality of life, including the
inconvenience of most of the maximally suppressive regimens currently available
(e.g., dietary change or large numbers of pills); the potential risk of developing drug
resistance despite early initiation of therapy; the potential for limiting future treatment
options due to cycling of the patient through the available drugs during early disease;
the potential risk of transmission of virus resistant to protease inhibitors and other
agents; the unknown durability of effect of the currently available therapies; and the
unknown long-term toxicity of some drugs. Thus, the decision to begin therapy in the
asymptomatic patient is complex and must be made in the setting of careful patient
counseling and education. The factors that must be considered in this decision include
the following: 1) the willingness of the individual to begin therapy; 2) the degree of
existing immunodeficiency as determined by the CD4+ T cell count; 3) the risk for
disease progression as determined by the level of plasma HIV RNA (Table 4; Figure);
4) the potential benefits and risks of initiating therapy in asymptomatic persons, as
discussed above; and 5) the likelihood, after counseling and education, of adherence
to the prescribed treatment regimen. In regard to adherence, no patient should auto-
matically be excluded from consideration for antiretroviral therapy simplyecause he
or she exhibits a behavior or other characteristic judged by some to lend itself to non-
compliance. The likelihood of patient adherence to a complex drug regimen should be
discussed and determined by the individual patient and physician before therapy is
initiated. To achieve the level of adherence necessary for effective therapy, providers
are encouraged to utilize strategies for assessing and assisting adherence that have
been developed in the context of chronic treatment for other serious diseases. Inten-
sive patient education regarding the critical need for adherence should be provided,
specific goals of therapy should be established and mutually agreed upon, and a long-
term treatment plan should be developed with the patient. Intensive follow-up should
take place to assess adherence to treatment and to continue patient counseling to
prevent transmission of HIV through sexual contact and injection of drugs.
Initiating Therapy in the Patient Who Has Asymptomatic HIV
Infection
Once the patient and physician have decided to initiate antiretroviral therapy, treat-
ment should be aggressive, with the goal of maximal suppression of plasma viral load
to undetectable levels. Recommendations regarding when to initiate therapy and
what regimens to use are provided (Tables 5 and 6). In general, any patient who has
<500 CD4+ T cells/mm3 or >10,000 (bDNA) or 20,000 (RT-PCR) copies of HIV RNA/mL of
plasma should be offered therapy (AII). However, the strength of the recommendation
for therapy should be based on the readiness of the patient for treatment and a con-
sideration of the prognosis for risk for progression to AIDS as determined by viral
load, CD4+ T cell count (Table 4; Figure), and the slope of the CD4+ T cell count decline.
The values for bDNA (Table 4; Figure, first column or line) are the uncorrected HIV RNA
values obtained from the Multicenter AIDS Cohort Study (MACS). It had previously
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been thought that these values, obtained on stored heparinized plasma specimens,
should be multiplied by a factor of two to adjust for an anticipated twofold loss of RNA
ascribed to the effects of heparin and delayed processing on the stability of RNA.
However, more recent analysis suggests that the reduction ascribed to these factors is
≤0.2 log, so that no significant correction factor is necessary (Mellors J, personal com-
munication, October 1997). RT-PCR values also are provided (Table 4; Figure);
comparison of the results obtained from the RT-PCR and bDNA assays, using the
manufacturer’s controls, consistently indicates that the HIV-1 RNA values obtained by
RT-PCR are approximately twice those obtained by the bDNA assay (12 ). Thus, the
MACS values must be multiplied by approximately 2 to be consistent with current
RT-PCR values. A third test for HIV RNA, the nucleic acid sequence based amplification
(NASBA®), is currently used in some clinical settings. However, formulas for convert-
ing values obtained from either branched DNA (bDNA) or RT-PCR assays to
NASBA®-equivalent values cannot be derived from the limited data currently avail-
able.
Currently, there are two general approaches to initiating therapy in the asympto-
matic patient: a) a therapeutically more aggressive approach in which most patients
would be treated early in the course of HIV infection due to the recognition that HIV
disease is virtually always progressive and b) a therapeutically more cautious ap-
proach in which therapy may be delayed because the balance of the risk for clinically
significant progression and other factors discussed above are considered to weigh in
favor of observation and delayed therapy. The aggressive approach is heavily based
on the Principles of Therapy, particularly the principle (see Principle 3) that one should
begin treatment before the development of significant immunosuppression and one
should treat to achieve undetectable viremia; thus, all patients who have <500 CD4+ T
cells/mm3 would be started on therapy as would patients who have higher CD4+ T cell
numbers and plasma viral load >10,000 (bDNA) or 20,000 (RT-PCR) (Table 5). The more
conservative approach to the initiation of therapy in the asymptomatic person would
delay treatment of the patient who has <500 CD4+ T cells/mm3 and low levels of vire-
mia and who has a low risk for rapid disease progression (Table 4); careful observation
and monitoring would continue. Patients who have CD4+ T cell counts >500/mm3
would also be observed, except those who are at substantial risk for rapid disease
progression because of a high viral load. For example, the patient who has 60,000
(RT-PCR) or 30,000 (bDNA) copies of HIV RNA/mL, regardless of CD4+ T cell count, has
a high probability of progressing to an AIDS-defining complication of HIV disease
within 3 years (32.6% if CD4+ T cells are >500/mm3) and should clearly be encouraged
to initiate antiretroviral therapy. Conversely, a patient who has 18,000 copies of HIV
RNA/mL of plasma, measured by RT-PCR, and a CD4+ T cell count of 410/mm3, has a
5.9% chance of progressing to an AIDS-defining complication of HIV infection in 3
years (Table 4). The therapeutically aggressive physician would recommend treatment
for this patient to suppress the ongoing viral replication that is readily detectable; the
therapeutically more conservative physician would discuss the possibility of initiation
of therapy but recognize that a delay in therapy because of the balance of considera-
tions previously discussed also is reasonable. In either case, the patient should make
the final decision regarding acceptance of therapy following discussion with the
health-care provider regarding specific issues relevant to his/her own clinical situ-
ation.
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When initiating therapy in the patient who has never been administered antiretrovi-
ral therapy, one should begin with a regimen that is expected to reduce viral
replication to undetectable levels (AIII). Based on the weight of experience, the pre-
ferred regimen to accomplish this consists of two nucleoside reverse transcriptase
inhibitors (NRTIs) and one potent protease inhibitor (PI) (Table 6). Alternative regi-
mens have been employed; these regimens include ritonavir and saquinavir (with one
or two NRTIs) or nevirapine as a substitute for the PI. Dual PI therapy with ritonavir
and saquinavir (hard-gel formulation), without an NRTI, appears to be potent in sup-
pressing viremia below detectable levels and has convenient twice-daily dosing;
however, the safety of this combination has not been fully established according to
FDA guidelines. Also, this regimen has not been directly compared with the proven
regimens of two NRTIs and a PI; thus, the Panel recommends that at least one addi-
tional NRTI be used when the physician elects to use two PIs as initial therapy.
Substituting nevirapine for the PI, or using two NRTIs alone, does not achieve the goal
of suppressing viremia to below detectable levels as consistently as does combination
treatment with two NRTIs and a PI and should be used only if more potent treatment
is not possible. However, some experts consider that there currently are insufficient
data to choose between a three-drug regimen containing a PI and one containing nevi-
rapine in the patient who has never been administered therapy; further studies are
pending. Other regimens using two PIs or a PI and a non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) as initial therapy are currently in clinical trials with data
pending. Of the two available NNRTIs, clinical trials support a preference for nevirap-
ine over delavirdine based on results of viral load assays. Although 3TC is a potent
NRTI when used in combination with another NRTI, in situations in which suppression
of virus replication is not complete, restance to 3TC develops rapidly (13,14). There-
fore, the optimal use for this agent is as part of a three-or-more drug combination that
has a high probability of complete suppression of virus replication. Other agents in
which a single genetic mutation can confer drug resistance (e.g., the NNRTIs nevirap-
ine and delavirdine) also should be used in this manner. Use of antiretroviral agents as
monotherapy is contraindicated (DI), except when no other options exist or during
pregnancy to reduce perinatal transmission. When initiating antiretroviral therapy, all
drugs should be started simultaneously at full dose with the following three excep-
tions: dose escalation regimens are recommended for ritonavir, nevirapine, and, in
some cases, ritonavir plus saquinavir.
Detailed information comparing the different NRTIs, the NNRTIs, the PIs, and drug
interactions between the PIs and other agents is provided (Tables 7–12). Particular at-
tention should be paid to drug interactions between the PIs and other agents (Tables
9–12), as these are extensive and often require dose modification or substitution of
various drugs. Toxicity assessment is an ongoing process; assessment at least twice
during the first month of therapy and every 3 months thereafter is a reasonable man-
agement approach.
Initiating Therapy in Patients Who Have Advanced-Stage
HIV Disease
All patients diagnosed as having advanced HIV disease, which is defined as any
condition meeting the 1993 CDC definition of AIDS (6), should be treated with an-
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tiretroviral agents regardless of plasma viral levels (AI). All patients who have symp-
tomatic HIV infection without AIDS, defined as the presence of thrush or unexplained
fever, also should be treated.
Special Considerations in the Patient Who Has Advanced-Stage HIV Disease
Some patients with OIs, wasting, dementia, or malignancy are first diagnosed with
HIV infection at this advanced stage of disease. All patients who have advanced HIV
disease should be treated with antiretroviral therapy. When the patient is acutely ill
with an OI or other complication of HIV infection, the clinician should consider clinical
issues (e.g., drug toxicity, ability to adhere to treatment regimens, drug interactions,
and laboratory abnormalities) when determining the timing of initiation of antiretrovi-
ral therapy. Once therapy is initiated, a maximally suppressive regimen (e.g., two
NRTIs and a PI) should be used (Table 6). Advanced-stage patients being maintained
on an antiretroviral regimen should not have the therapy discontinued during an acute
OI or malignancy, unless concerns exist regarding drug toxicity, intolerance, or drug
interactions.
Patients who have progressed to AIDS often are treated with complicated combina-
tions of drugs, and the clinician and patient should be alert to the potential for multiple
drug interactions. Thus, the choice of which antiretroviral agents to use must be made
with consideration given to potential drug interactions and overlapping drug toxicities
(Tables 7–12). For instance, the use of rifampin to treat active tuberculosis is problem-
atic in a patient who is being administered a PI, which adversely affects the
metabolism of rifampin but is frequently needed to effectively suppress viral replica-
tion in these advanced patients. Conversely, rifampin lowers the blood level of PIs,
which may result in suboptimal antiretroviral therapy. Although rifampin is contrain-
dicated or not recommended for use with all of the PIs, the clinician might consider
using a reduced dose of rifabutin (Tables 8–11); this topic is discussed in greater detail
elsewhere (15 ). Other factors complicating advanced disease are wasting and ano-
rexia, which may prevent patients from adhering to the dietary requirements for
efficient absorption of certain protease inhibitors. Bone marrow suppression associ-
ated with ZDV and the neuropathic effects of ddC, d4T and ddI may combine with the
direct effects of HIV to render the drugs intolerable. Hepatotoxicity associated with
certain PIs may limit the use of these drugs, especially in patients who have underly-
ing liver dysfunction. The absorption and half life of certain drugs may be altered by
antiretroviral agents, particularly the PIs and NNRTIs whose metabolism involves the
hepatic cytochrome p450 (CYP450) enzymatic pathway. Some of these PIs and NNRTIs
(i.e., ritonavir, indinavir, saquinavir, nelfinavir, and delavirdine) inhibit the CYP450
pathway; others (e.g., nevirapine) induce CYP450 metabolism. CYP450 inhibitors have
the potential to increase blood levels of drugs metabolized by this pathway. Adding a
CYP450 inhibitor can sometimes improve the pharmacokinetic profile of selected
agents (e.g., adding ritonavir therapy to the hard-gel formulation of saquinavir) as well
as contribute an additive antiviral effect; however, these interactions also can result in
life-threatening drug toxicity (Tables 10–12). As a result, health-care providers should
inform their patients of the need to discuss any new drugs, including over-the-counter
agents and alternative medications, that they may consider taking, and careful atten-
tion should be given to the relative risk versus benefits of specific combinations of
agents.
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Initiation of potent antiretroviral therapy often is associated with some degree of
recovery of immune function. In this setting, patients who have advanced HIV disease
and subclinical opportunistic infections (e.g., mycobacterium avium intracellulare
[MAI] or CMV) may develop a new immunologic response to the pathogen, and, thus,
new symptoms may develop in association with the heightened immunologic and/or
inflammatory response. This should not be interpreted as a failure of antiretroviral
therapy, and these newly presenting OIs should be treated appropriately while main-
taining the patient on the antiretroviral regimen. Viral load measurement is helpful in
clarifying this association.
INTERRUPTION OF ANTIRETROVIRAL THERAPY
There are multiple reasons for temporary discontinuation of antiretroviral therapy,
including intolerable side effects, drug interactions, first trimester of pregnancy when
the patient so elects, and unavailability of drug. There are no currently available stud-
ies and therefore no reliable estimate of the number of days, weeks or months that
constitute a clinically important interruption of one or more components of a thera-
peutic regimen that would increase the likelihood of drug resistance. If any
antiretroviral medication has to be discontinued for an extended time, clinicians and
patients should be aware of the theoretical advantage of stopping all antiretroviral
agents simultaneously, rather than continuing one or two agents, to minimize the
emergence of resistant viral strains (see Principle 4).
CHANGING A FAILING REGIMEN
Considerations for Changing a Failing Regimen
The decision to change regimens should be approached with careful consideration
of several complex factors. These factors include recent clinical history and physical
examination; plasma HIV RNA levels measured on two separate occasions; absolute
CD4+ T cell count and changes in these counts; remaining treatment options in terms
of potency, potential resistance patterns from prior antiretroviral therapies, and poten-
tial for adherence/tolerance; assessment of adherence to medications; and
psychological preparation of the patient for the implications of the new regimen (e.g.,
side effects, drug interactions, dietary requirements and possible need to alter con-
comitant medications) (see Principle 7). Failure of a regimen may occur for many
reasons: initial viral resistance to one or more agents, altered absorption or metabo-
lism of the drug, multidrug pharmacokinetics that adversely affect therapeutic drug
levels, and poor patient adherence to a regimen due to either poor compliance or
inadequate patient education about the therapeutic agents. In regard to the last issue,
the health-care provider should carefully assess patient adherence before changing
antiretroviral therapy; health-care workers involved in the care of the patient (e.g., the
case manager or social worker) may be helpful in this evaluation. Clinicians should be
aware of the prevalence of mental health disorders and psychoactive substance use
disorders in certain HIV-infected persons; inadequate mental health treatment serv-
ices may jeopardize the ability of these persons to adhere to their medical treatment.
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Proper identification of and intervention in these mental health disorders can greatly
enhance adherence to medical HIV treatment.
It is important to distinguish between the need to change therapy because of drug
failure versus drug toxicity. In the latter case, it is appropriate to substitute one or
more alternative drugs of the same potency and from the same class of agents as the
agent suspected to be causing the toxicity. In the case of drug failure where more than
one drug had been used, a detailed history of current and past antiretroviral medica-
tions, as well as other HIV-related medications, should be obtained. Optimally and
when possible, the regimen should be changed entirely to drugs that have not been
taken previously. With triple combinations of drugs, at least two and preferably three
new drugs must be used; this recommendation is based on the current understanding
of strategies to prevent drug resistance (see Principles 4 and 5). Assays to determine
genotypic resistance are commercially available; however, these have not undergone
field testing to demonstrate clinical utility and are not approved by the FDA. The Panel
does not recommend these assays for routine use at present.
The following three categories of patients should be considered with regard to a
change in therapy: 1) persons who are receiving incompletely suppressive antiretrovi-
ral therapy with single or double nucleoside therapy and with detectable or
undetectable plasma viral load; 2) persons who have been on potent combination
therapy, including a PI, and whose viremia was initially suppressed to undetectable
levels but has again become detectable; and 3) persons who have been on potent
combination therapy, including a PI, and whose viremia was never suppressed to be-
low detectable limits. Although persons in these groups should have treatment
regimens changed to maximize the chances of durable, maximal viral RNA suppres-
sion, the first group may have more treatment options because they are PI naive.
Criteria for Changing Therapy
The goal of antiretroviral therapy, which is to improve the length and quality of the
patient’s life, is likely best accomplished by maximal suppression of viral replication to
below detectable levels (currently defined as <500 copies/mL) sufficiently early to pre-
serve immune function. However, this reduction cannot always be achieved with a
given therapeutic regimen, and frequently regimens must be modified. In general, the
plasma HIV RNA level is the most important parameter to consider in evaluating re-
sponse to therapy, and increases in levels of viremia that are substantial, confirmed,
and not attributable to intercurrent infection or vaccination indicate failure of the drug
regimen, regardless of changes in the CD4+ T cell counts. Clinical complications and
sequential changes in CD4+ T cell count may complement the viral load test in evalu-
ating a response to treatment. Specific criteria that should prompt consideration for
changing therapy include the following:
• Less than a 0.5–0.75 log reduction in plasma HIV RNA by 4–8 weeks following
initiation of therapy (CIII).
• Failure to suppress plasma HIV RNA to undetectable levels within 4–6 months of
initiating therapy (BIII). The degree of initial decrease in plasma HIV RNA and the
overall trend in decreasing viremia should be considered. For instance, a patient
with 10
6
 viral copies/mL prior to therapy who stabilizes after 6 months of therapy
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at an HIV RNA level that is detectable but <10,000 copies/mL may not warrant an
immediate change in therapy.
• Repeated detection of virus in plasma after initial suppression to undetectable
levels, suggesting the development of resistance (BIII). However, the degree of
plasma HIV RNA increase should be considered; the physician may consider
short-term further observation in a patient whose plasma HIV RNA increases
from undetectable to low-level detectability (e.g., 500–5,000 copies/mL) at
4 months. In this situation, the patient should be monitored closely. However,
most patients whose plasma HIV RNA levels become detectable after having
been undetectable will subsequently show progressive increases in plasma vire-
mia that will likely require a change in antiretroviral regimen.
• Any reproducible significant increase, defined as threefold or greater, from the
nadir of plasma HIV RNA not attributable to intercurrent infection, vaccination, or
test methodology except as noted above (BIII).
• Undetectable viremia in the patient who is being administered double nucleoside
therapy (BIII). Patients currently receiving two NRTIs who have achieved the goal
of no detectable virus have the option of either continuing this regimen or modi-
fying the regimen to conform to regimens in the preferred category (Table 6).
Prior experience indicates that most of these patients on double nucleoside ther-
apy will eventually have virologic failure with a frequency that is substantially
greater compared with patients treated with the preferred regimens.
• Persistently declining CD4+ T cell numbers, as measured on at least two separate
occasions (see Principle 2 for significant decline) (CIII).
• Clinical deterioration (DIII). A new AIDS-defining diagnosis that was acquired af-
ter the time treatment was initiated suggests clinical deterioration but may or
may not suggest failure of antiretroviral therapy. If the antiretroviral effect of
therapy was poor (e.g., a less than tenfold reduction in viral RNA), then a judg-
ment of therapeutic failure could be made. However, if the antiretroviral effect
was good but the patient was already severely immunocompromised, the ap-
pearance of a new opportunistic disease may not necessarily reflect a failure of
antiretroviral therapy, but rather a persistence of severe immunocompromise
that did not improve despite adequate suppression of virus replication. Similarly,
an accelerated decline in CD4+ T cell counts suggests progressive immune defi-
ciency providing there are sufficient measurements to ensure quality control of
CD4+ T cell measurements.
A final consideration in the decision to change therapy is the recognition of the still
limited choice of available agents and the knowledge that a decision to change may
reduce future treatment options for the patient (see Principle 7). This consideration
may influence the physician to be somewhat more conservative when deciding to
change therapy. Consideration of alternative options should include potency of the
substituted regimen and probability of tolerance of or adherence to the alternative
regimen. Clinical trials have demonstrated that partial suppression of virus is superior
to no suppression of virus. However, some physicians and patients may prefer to sus-
pend treatment to preserve future options or because a sustained antiviral effect
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cannot be achieved. Referral to or consultation with an experienced HIV clinician is
appropriate when the clinician is considering a change in therapy. When possible, pa-
tients who require a change in an antiretroviral regimen but without treatment options
that include using currently approved drugs should be referred for consideration for
inclusion in an appropriate clinical trial.
Therapeutic Options When Changing Antiretroviral Therapy
Recommendations for changes in treatment differ according to the indication for
the change. If the desired virologic objectives have been achieved in patients who
have intolerance or toxicity, a substitution should be made for the offending drug,
preferably with an agent in the same class with a different toxicity or tolerance profile.
If virologic objectives have been achieved but the patient is receiving a regimen not in
the preferred category (e.g., two NRTIs or monotherapy), there is the option either to
continue treatment with careful monitoring of viral load or to add drugs to the current
regimen to comply with preferred treatment regimens. Most experts consider that
treatment with regimens not in the preferred category is associated with eventual fail-
ure and recommend the latter tactic. At present, few clinical data are available to
support specific strategies for changing therapy in patients who have failed the pre-
ferred regimens that include PIs; however, several theoretical considerations should
guide decisions. Because of the relatively rapid mutability of HIV, viral strains that are
resistant to one or more agents often emerge during therapy, particularly when viral
replication has not been maximally suppressed. Of major concern is recent evidence
of broad cross-resistance among the class of PIs. Evidence indicates that viral strains
that become resistant to one PI will have reduced susceptibility to most or all other PIs.
Thus, the likelihood of success of a subsequently administered PI + two NRTI regimen,
even if all drugs are different from the initial regimen, may be limited, and many ex-
perts would include two new PIs in the subsequent regimen.
Some of the most important guidelines to follow when changing a patient’s an-
tiretroviral therapy are summarized (Table 13), and some of the treatment options
available when a decision has been made to change the antiretroviral regimen are
outlined (Table 14). Limited data exist to suggest that any of these alternative regi-
mens will be effective (Table 14), and careful monitoring and consultation with an
expert in the care of such HIV-infected patients is desirable. A change in regimen be-
cause of treatment failure should ideally involve complete replacement of the regimen
with different drugs to which the patient is naive. This typically would include the use
of two new NRTIs and one new PI or NNRTI, two PIs with one or two new NRTIs, or a
PI combined with an NNRTI. Dose modifications may be required to account for drug
interactions when using combinations of PIs or a PI and NNRTI (Table 12). In some
persons, these options are not possible because of prior antiretroviral use, toxicity, or
intolerance. In the clinically stable patient who has detectable viremia for whom an
optimal change in therapy is not possible, it may be prudent to delay changing ther-
apy in anticipation of the availability of newer and more potent agents. It is
recommended that the decision to change therapy and design a new regimen should
be made with assistance from a clinician experienced in the treatment of HIV infected
patients through consultation or referral.
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ACUTE HIV INFECTION
Considerations for Treatment of Patients Who Have Acute HIV
Infection
Various studies indicate that 50%–90% of patients acutely infected with HIV will
experience at least some symptoms of the acute retroviral syndrome (Table 15) and
can thus be identified as candidates for early therapy (16–19 ). However, acute HIV
infection is often not recognized in the primary-care setting because of the similarity
of the symptom complex with those of the “flu” or other common illnesses. Also,
acute primary infection may occur without symptoms. Physicians should maintain a
high level of suspicion for HIV infection in all patients with a compatible clinical syn-
drome (Table 15) and should obtain appropriate laboratory confirmation. Information
regarding treatment of acute HIV infection from clinical trials is limited. There is evi-
dence for a short-term effect of therapy on viral load and CD4+ T cell counts (20 ), but
there are as yet no outcome data demonstrating a clinical benefit of antiretroviral
treatment of primary HIV infection. Clinical trials completed to date also have been
limited by small sample sizes, short duration of follow-up, and often by the use of
treatment regimens that have suboptimal antiviral activity by current standards. How-
ever, results from these studies generally support antiretroviral treatment of acute HIV
infection. Ongoing clinical trials are addressing the question of the long-term clinical
benefit of more potent treatment regimens.
The theoretical rationale for early intervention (see Principle 10) is fourfold:
• to suppress the initial burst of viral replication and decrease the magnitude of
virus dissemination throughout the body;
• to decrease the severity of acute disease;
• to potentially alter the initial viral “set-point”, which may ultimately affect the
rate of disease progression;
• to possibly reduce the rate of viral mutation due to the suppression of viral repli-
cation.
The physician and the patient should be aware that therapy of primary HIV infec-
tion is based on theoretical considerations, and the potential benefits, described
above, should be weighed against the potential risks (see below). Most experts en-
dorse treatment of acute HIV infection based on the theoretical rationale, limited but
supportive clinical trial data, and the experience of HIV clinicians.
The risks associated with therapy for acute HIV infection include adverse effects on
quality of life resulting from drug toxicities and dosing constraints; the potential, if
therapy fails to effectively suppress viral replication, for the development of drug re-
sistance that may limit future treatment options; and the potential need for continuing
therapy indefinitely. These considerations are similar to those for initiating therapy in
the asymptomatic patient (see Considerations in Initiating Therapy in the Asympto-
matic HIV-infected Patient).
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Deciding Whom to Treat During Acute HIV Infection
Many experts would recommend antiretroviral therapy for all patients who demon-
strate laboratory evidence of acute HIV infection (AII). Such evidence includes HIV
RNA in plasma that can be detected by using sensitive PCR or bDNA assays together
with a negative or indeterminate HIV antibody test. Although measurement of plasma
HIV RNA is the preferable method of diagnosis, a test for p24 antigen may be useful
when RNA testing is not readily available. However, a negative p24 antigen test does
not rule out acute infection. When suspicion for acute infection is high (e.g., as in a
patient who has a report of recent risk behavior in association with suggestive symp-
toms and signs [Table 15]), a test for HIV RNA should be performed (BII).* Persons
may or may not have symptoms of the acute retroviral syndrome. Viremia occurs
acutely after infection before the detection of a specific immune response; an indeter-
minate antibody test may occur when a person is in the process of seroconversion.
Apart from patients who have acute primary HIV infection, many experts also
would consider therapy for patients in whom seroconversion has been documented
to have occurred within the previous 6 months (CIII). Although the initial burst of vire-
mia in infected adults has usually resolved by 2 months, treatment during the
2–6–month period after infection is based on the likelihood that virus replication in
lymphoid tissue is still not maximally contained by the immune system during this
time. Decisions regarding therapy for patients who test antibody positive and who
believe the infection is recent but for whom the time of infection cannot be docu-
mented should be made using the Asymptomatic HIV Infection algorithm mentioned
previously (CIII). No patient should be treated for HIV infection until the infection is
documented, except in the setting of post-exposure prophylaxis of health-care work-
ers with antiretroviral agents (21 )†. All patients without a formal medical record of a
positive HIV test (e.g., persons who have tested positive by available home testing
kits) should be tested by both the ELISA and an established confirmatory test (e.g., the
Western Blot) to document HIV infection (AI).
Treatment Regimen for Primary HIV Infection
Once the physician and patient have decided to use antiretroviral therapy for pri-
mary HIV infection, treatment should be implemented with the goal of suppressing
plasma HIV RNA levels to below detectable levels (AIII). The weight of current experi-
ence suggests that the therapeutic regimen for acute HIV infection should include a
combination of two NRTIs and one potent PI (AII). Although most experience to date
with PIs in the setting of acute HIV infection has been with ritonavir, indinavir or nelfi-
navir (2,22–24 ), insufficient data are available to make firm conclusions regarding
specific drug recommendations. Potential combinations of agents available are much
the same as those used in established infection (Table 6). These aggressive regimens
may be associated with several disadvantages (e.g., drug toxicity, large numbers of
pills, cost of drugs, and the possibility of developing drug resistance that may limit
future options); the latter is likely if virus replication is not adequately suppressed or if
the patient has been infected with a viral strain that is already resistant to one or more
*Patients diagnosed with HIV infection by HIV RNA testing should have confirmatory testing
performed (Table 2).
†Or treatment of neonates born to HIV-infected mothers.
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agents. The patient should be carefully counseled regarding these potential limita-
tions and individual decisions made only after weighing the risks and sequelae of
therapy against the theoretical benefit of treatment.
Any regimen that is not expected to maximally suppress viral replication is not
considered appropriate for treating the acutely HIV-infected person (EIII) because a)
the ultimate goal of therapy is suppression of viral replication to below the level of
detection, b) the benefits of therapy are based primarily on theoretical considerations,
and c) long-term clinical outcome benefit has not been documented. Additional clini-
cal studies are needed to delineate further the role of antiretroviral therapy in the
primary infection period.
Patient Follow-up
Testing for plasma HIV RNA levels and CD4+ T cell count and toxicity monitoring
should be performed as previously described in Use of Testing for Plasma HIV RNA
levels and CD4+ T Cell Count in Guiding Decisions for Therapy, that is, on initiation of
therapy, after 4 weeks, and every 3–4 months thereafter (AII). Some experts suggest
that testing for plasma HIV RNA levels at 4 weeks is not helpful in evaluating the effect
of therapy for acute infection because viral loads may be decreasing from peak vire-
mia levels even in the absence of therapy.
Duration of Therapy for Primary HIV Infection
Once therapy is initiated, many experts would continue to treat the patient with
antiretroviral agents indefinitely because viremia has been documented to reappear
or increase after discontinuation of therapy (CII). However, some experts would treat
for one year and then reevaluate the patient with CD4+ T cell determinations and
quantitative HIV RNA measurements. The optimal duration and composition of ther-
apy are unknown, and ongoing clinical trials are expected to provide data relevant to
these issues. The difficulties inherent in determining the optimal duration and compo-
sition of therapy initiated for acute infection should be considered when first
counseling the patient regarding therapy.
CONSIDERATIONS FOR ANTIRETROVIRAL THERAPY IN THE
HIV-INFECTED ADOLESCENT
HIV-infected adolescents who were infected through sexual contact or through in-
jecting-drug use during adolescence appear to follow a clinical course that is more
similar to HIV disease in adults than in children. In contrast, adolescents who were
infected perinatally or through blood products as young children have a unique clini-
cal course that may differ from other adolescents and long-term surviving adults.
Currently, most HIV-infected adolescents were infected through sexual contact during
the adolescent period and are in a relatively early stage of infection, making them
ideal candidates for early intervention.
Puberty is a time of somatic growth and hormonally mediated changes, with fe-
males developing more body fat and males more muscle mass. Although theoretically
these physiologic changes could affect drug pharmacology, particularly in the case of
drugs with a narrow therapeutic index that are used in combination with protein-
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bound medicines or hepatic enzyme inducers or inhibitors, no clinically substantial
impact of puberty on the use of NRTIs has been observed. Clinical experience with PIs
and NNRTIs has been limited. Thus, it is currently recommended that medications
used to treat HIV and OIs in adolescents should be administered in a dosage based on
Tanner staging of puberty and not specific age. Adolescents in early puberty (Tanner
I–II) should receive doses as recommended in the pediatric guidelines, whereas those
in late puberty (Tanner V) should receive doses recommended in the adult guidelines.
Youth who are in the midst of their growth spurt (Tanner III females and Tanner IV
males) should be closely monitored for medication efficacy and toxicity when choos-
ing adult or pediatric dosing guidelines.
CONSIDERATIONS FOR ANTIRETROVIRAL THERAPY IN THE
PREGNANT HIV-INFECTED WOMAN
Guidelines for optimal antiretroviral therapy and for initiation of therapy in preg-
nant HIV-infected women should be the same as those delineated for nonpregnant
adults (see Principle 8). Thus, the woman’s clinical, virologic, and immunologic status
should be the primary factor in guiding treatment decisions. However, it must be real-
ized that the potential impact of such therapy on the fetus and infant is unknown. The
decision to use any antiretoviral drug during pregnancy should be made by the
woman following discussion with her health-care provider regarding the known and
unknown benefits and risks to her and her fetus. Long-term follow-up is recom-
mended for all infants born to women who have received antiretroviral drugs during
pregnancy.
Women who are in the first trimester of pregnancy and who are not receiving an-
tiretroviral therapy may wish to consider delaying initiation of therapy until after
10–12 weeks’ gestation because this is the period of organogenesis when the embryo
is most susceptible to potential teratogenic effects of drugs; the risks of antiretroviral
therapy to the fetus during that period are unknown. However, this decision should be
carefully considered and discussed between the health-care provider and the patient
and should include an assessment of the woman’s health status and the potential
benefits and risks of delaying initiation of therapy for several weeks. If clinical, vi-
rologic, or immunologic parameters are such that therapy would be recommended for
nonpregnant persons, many experts would recommend initiating therapy, regardless
of gestational age. Nausea and vomiting in early pregnancy, which affect the ability to
adequately take and absorb oral medications, may be a factor in deciding whether to
administer treatment during the first trimester.
Some women already receiving antiretroviral therapy may have their pregnancy
diagnosed early enough in gestation that concern for potential teratogenicity may
lead them to consider temporarily stopping antiretroviral therapy until after the first
trimester. Insufficient data exist that either support or refute teratogenic risk of an-
tiretroviral drugs when administered during the first 10–12 weeks’ gestation. However,
a rebound in viral levels would be anticipated during the period of discontinuation,
and this rebound could theoretically be associated with increased risk of early in utero
HIV transmission or could potentiate disease progression in the woman (25 ). Al-
though the effects of all antiretroviral drugs on the developing fetus during the first
trimester are uncertain, most experts recommend continuation of a maximally sup-
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pressive regimen even during the first trimester. If antiretroviral therapy is discontin-
ued during the first trimester for any reason, all agents should be stopped
simultaneously to avoid development of resistance. Once the drugs are reinstituted,
they should be introduced simultaneously for the same reason.
The choice of which antiretroviral agents to use in pregnant women is subject to
unique considerations (see Principle 8). Currently, minimal data are available regard-
ing the pharmacokinetics and safety of antiretroviral agents during pregnancy for
drugs other than ZDV. In the absence of data, drug choice needs to be individualized
based on discussion with the patient and available data from preclinical and clinical
testing of the individual drugs. The FDA pregnancy classification for all currently ap-
proved antiretroviral agents and selected other information relevant to the use of
antiretroviral drugs in pregnancy is provided (Table 16). The predictive value of in vitro
and animal-screening tests for adverse effects in humans is unknown. Many drugs
commonly used to treat HIV infection or its consequences may have positive findings
on one or more of these screening tests. For example, acyclovir is positive on some in
vitro assays for chromosomal breakage and carcinogenicity and is associated with
some fetal abnormalities in rats; however, data on human experience from the Acy-
clovir in Pregnancy Registry indicate no increased risk of birth defects to date in
infants with in utero exposure to acyclovir (26 ).
Of the currently approved nucleoside analogue antiretroviral agents, the pharma-
cokinetics of only ZDV and 3TC have been evaluated in infected pregnant women to
date (27,28 ). Both drugs seem to be well tolerated at the usual adult doses and cross
the placenta, achieving concentrations in cord blood similar to those observed in ma-
ternal blood at delivery. All the nucleosides except ddI have preclinical animal studies
that indicate potential fetal risk and have been classified as FDA pregnancy category C
(Table 16); ddI has been classified as category B. In primate studies, all the nucleoside
analogues seem to cross the placenta, but ddI and ddC apparently have significantly
less placental transfer (fetal to maternal drug ratios of 0.3 to 0.5) than do ZDV, d4T, and
3TC (fetal to maternal drug ratios >0.7) (29 ).
Of the NNRTIs, only nevirapine administered once at the onset of labor has been
evaluated in pregnant women. The drug was well tolerated after a single dose and
crossed the placenta and achieved neonatal blood concentrations equivalent to those
in the mother. The elimination of nevirapine administered during labor in the pregnant
women in this study was prolonged (mean half-life following a single dose, 66 hours)
compared with nonpregnant persons (mean half-life following a single dose, 45
hours). Data on multiple dosing during pregnancy are not yet available. Delavirdine
has not been studied in Phase I pharmacokinetic and safety trials in pregnant women.
In premarketing clinical studies, outcomes of seven unplanned pregnancies were re-
ported. Three of these were ectopic pregnancies, and three resulted in healthy live
births. One infant was born prematurely, with a small ventricular septal defect, to a
patient who had received approximately 6 weeks of treatment with delavirdine and
ZDV early in the course of pregnancy.
Although studies of combination therapy with protease inhibitors in pregnant HIV-
infected women are in progress, no data are currently available regarding drug
dosage, safety and tolerance during pregnancy. In mice, indinavir has substantial pla-
cental passage; however, in rabbits, little placental passage was observed. Ritonavir
has been demonstrated to have some placental passage in rats. There are some spe-
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cial theoretical concerns regarding the use of indinavir late in pregnancy. Indinavir is
associated with side effects (hyperbilirubinemia and renal stones) that theoretically
could be problematic for the newborn if transplacental passage occurs and the drug is
administered shortly before delivery. These side effects are particularly problematic
because the immaturity of the metabolic enzyme system of the neonatal liver would
likely be associated with prolonged drug half-life leading to extended drug exposure
in the newborn that could lead to potential exacerbation of physiologic neonatal hy-
perbilirubinemia. Because of immature neonatal renal function and the inability of the
neonate to voluntarily ensure adequate hydration, high drug concentrations and/or
delayed elimination in the neonate could result in a higher risk for drug crystallization
and renal stone development than observed in adults. These concerns are theoretical
and such effects have not been reported; because the half-life of indinavir in adults is
short, these concerns may only be relevant if drug is administered near the time of
labor. Gestational diabetes is a pregnancy-related complication that can develop in
some women; administration of any of the four currently available protease inhibitors
has been associated with new onset diabetes mellitus, hyperglycemia, or exacerba-
tion of existing diabetes mellitus in HIV-infected patients (30 ). Pregnancy is itself a risk
factor for hyperglycemia, and it is unknown if the use of protease inhibitors will exac-
erbate this risk for hyperglycemia. Health-care providers caring for infected pregnant
women who are being administered PI therapy should be aware of the possibility of
hyperglycemia and closely monitor glucose levels in their patients and instruct their
patients on how to recognize the early symptoms of hyperglycemia.
To date, the only drug that has been shown to reduce the risk of perinatal HIV trans-
mission is ZDV when administered according to the following regimen: orally
administered antenatally after 14 weeks’ gestation and continued throughout preg-
nancy, intravenously administered during the intrapartum period, and administered
orally to the newborn for the first 6 weeks of life (31 ). This chemoprophylactic regi-
men was shown to reduce the risk for perinatal transmission by 66% in a randomized,
double-blind clinical trial, pediatric ACTG 076 (32 ). Insufficient data are available to
justify the substitution of any antiretroviral agent other than ZDV to reduce perinatal
HIV transmission; further research should address this question. For the time being, if
combination antiretroviral drugs are administered to the pregnant woman for treat-
ment of her HIV infection, ZDV should be included as a component of the antenatal
therapeutic regimen whenever possible, and the intrapartum and neonatal ZDV com-
ponents of the chemoprophylactic regimen should be administered to reduce the risk
for perinatal transmission. If a woman is not administered ZDV as a component of her
antenatal antiretroviral regimen (e.g., because of prior history of nonlife-threatening
ZDV-related severe toxicity or personal choice), intrapartum and newborn ZDV should
continue to be recommended; when use of ZDV is contraindicated in the woman, the
intrapartum component may be deleted, but the newborn component is still recom-
mended. ZDV and d4T should not be administered together due to potential
pharmacologic antagonism. When d4T is a preferred nucleoside for treatment of a
pregnant woman, it is recommended that antenatal ZDV not be added to the regimen;
however, intrapartum and neonatal ZDV should still be given.
The time-limited use of ZDV alone during pregnancy for chemoprophylaxis of per-
inatal transmission is controversial. The potential benefits of standard combination
antiretroviral regimens for treatment of HIV infection should be discussed with and
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offered to all pregnant HIV-infected women. Some women may wish to restrict expo-
sure of their fetus to antiretroviral drugs during pregnancy but still wish to reduce the
risk of transmitting HIV to their infant. For women in whom initiation of antiretroviral
therapy for treatment of their HIV infection would be considered optional (e.g., CD4+
count >500/mm3 and plasma HIV RNA <10,0000–20,000 RNA copies/mL), time-limited
use of ZDV during the second and third trimesters of pregnancy is less likely to induce
the development of resistance due to the limited viral replication existing in the pa-
tient and the time-limited exposure to the antiretroviral drug. For example, the
development of resistance was unusual among the healthy population of women who
participated in Pediatric (P)-ACTG 076 (33 ). The use of ZDV chemoprophylaxis alone
during pregnancy might be an appropriate option for these women. However, for
women who have more advanced disease and/or higher levels of HIV RNA, concerns
about resistance are greater and these women should be counseled that a combina-
tion antiretroviral regimen that includes ZDV for reducing transmission risk would be
more optimal for their own health than use of ZDV chemoprophylaxis alone.
Monitoring and use of HIV-1 RNA for therapeutic decision making during preg-
nancy should be performed as recommended for nonpregnant persons. Transmission
of HIV from mother to infant can occur at all levels of maternal HIV-1 RNA. In untreated
women, higher HIV-1 RNA levels correlate with increased transmission risk. However,
in ZDV-treated women this relationship is markedly attenuated (32 ). ZDV is effective
in reducing transmission regardless of maternal HIV RNA level. Therefore, the use of
the full ZDV chemoprophylaxis regimen, including intravenous ZDV during delivery
and the administration of ZDV to the infant for the first 6 weeks of life, alone or in
combination with other antiretrovirals, should be discussed with and offered to all
infected pregnant women regardless of their HIV-1 RNA level. Health-care providers
who are treating HIV-infected pregnant women are strongly encouraged to report
cases of prenatal exposure to antiretroviral drugs (either administered alone or in
combinations) to the Antiretroviral Pregnancy Registry. The registry collects observa-
tional, nonexperimental data regarding antiretroviral exposure during pregnancy for
the purpose of assessing potential teratogenicity. Registry data will be used to supple-
ment animal toxicology studies and assist clinicians in weighing the potential risks
and benefits of treatment for individual patients. The registry is a collaborative project
with an advisory committee of obstetric and pediatric practitioners, staff from CDC
and NIH, and staff from pharmaceutical manufacturers. The registry allows the ano-
nymity of patients, and birth outcome follow-up is obtained by registry staff from the
reporting physician. Referrals should be directed to Antiretroviral Pregnancy Registry,
Post Office Box 13398, Research Triangle Park, NC 27709-3398; telephone (800) 258-
4263.
CONCLUSION
The Panel has attempted to use the advances in current understanding of the
pathogenesis of HIV in the infected person to translate scientific principles and data
obtained from clinical experience into recommendations that can be used by the clini-
cian and patient to make therapeutic decisions. The recommendations are offered in
the context of an ongoing dialogue between the patient and the clinician after having
defined specific therapeutic goals with an acknowledgment of uncertainties. It is nec-
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essary for the patient to receive a continuum of medical care and services, including
social, psychosocial, and nutritional services, with the availability of expert referral
and consultation. To achieve the maximal flexibility in tailoring therapy to each patient
over the duration of his or her infection, it is imperative that drug formularies allow for
all FDA-approved NRTI, NNRTI, and PI as treatment options. The Panel strongly urges
industry and the public and private sectors to conduct further studies to allow refine-
ment of these guidelines. Specifically, studies are needed to optimize
recommendations for first-line therapy; to define second-line therapy; and to more
clearly delineate the reason(s) for treatment failure. The Panel remains committed to
revising their recommendations as such new data become available.
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>30K 10K–30K 3K–10K 501–3K <500
FIGURE 1. Likelihood of developing AIDS within 3 years*
*Viral load values represent the actual data obtained on the specimens from the Multicenter
AIDS Cohort Study (MACS) as well as the values showing the equivalent expected RT-PCR
values. Values shown in this figure differ slightly from those in Table 4 because better dis-
crimination of outcome was achieved by reanalysis of the data using viral load as the initial
parameter for categorization followed by CD4+ T cell stratification of the patients. (Adapted
from [12].)
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TABLE 1. Rating system for strength of recommendation and quality of evidence
supporting the recommendation
Category Definition
Categories reflecting the strength of each recommendation
A Strong; should always be offered
B Moderate; should usually be offered
C Optional
D Should generally not be offered
E Should never be offered
Categories reflecting the quality of evidence supporting the recommendation
I At least one randomized trial with clinical endpoints
II Clinical trials with laboratory endpoints
III Expert opinion
TABLE 2. Indications for plasma HIV RNA testing*




HIV antibody test is
negative or indeterminate
Diagnosis†
Initial evaluation of newly
diagnosed HIV infection
Baseline viral load “set
point”
Decision to start or defer
therapy
Every 3–4 mos. in patients
not on therapy
Changes in viral load Decision to start therapy
4–8 wks. after initiation of
antiretroviral therapy
Initial assessment of drug
efficacy
Decision to continue or
change therapy
3–4 mos. after start of
therapy
Maximal effect of therapy Decision to continue or
change therapy




Decision to continue or
change therapy
Clinical event or significant
decline in CD4+ T cells
Association with changing
or stable viral load
Decision to continue,
initiate, or change therapy
*Acute illness (e.g., bacterial pneumonia, tuberculosis, HSV, PCP) and immunizations can cause
increases in plasma HIV RNA for 2–4 wks.; viral load testing should not be performed during
this time. Plasma HIV RNA results should usually be verified with a repeat determination before
starting or making changes in therapy. HIV RNA should be measured using the same laboratory
and the same assay.
†Diagnosis of HIV infection determined by HIV RNA testing should be confirmed by standard
methods (e.g., Western blot serology) performed 2–4 mos. after the initial indeterminate or
negative test.
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TABLE 3. Risks and benefits of early initiation of antiretroviral therapy in the
asymptomatic HIV-infected patient
Potential Benefits
Control of viral replication and mutation; reduction of viral burden
Prevention of progressive immunodeficiency; potential maintenance or reconstitution of a
normal immune system
Delayed progression to AIDS and prolongation of life
Decreased risk of selection of resistant virus
Decreased risk of drug toxicity
Potential Risks
Reduction in quality of life from adverse drug effects and inconvenience of current maximally
suppressive regimens
Earlier development of drug resistance
Limitation in future choices of antiretroviral agents due to development of resistance
Unknown long-term toxicity of antiretroviral drugs
Unknown duration of effectiveness of current antiretroviral therapies
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TABLE 4. Risk for progression to AIDS-defining illness in a cohort of men who have
sex with men, predicted by baseline CD4+ T cell count and viral load*




study 3 yrs 6 yrs 9 yrs
        ≤500        ≤1,500  —¶ — — —
    501–3,000   1,501–7,000 30 0 18.8 30.6
 3,001–10,000  7,001–20,000 51  8.0 42.2 65.6
10,001–30,000 20,001–55,000 73 40.1 72.9 86.2
      >30,000       >55,000 174 72.9 92.7 95.6




study 3 yrs 6 yrs 9 yrs
        ≤500        ≤1,500 — — — —
    501–3,000   1,501–7,000  47  4.4 22.1 46.9
 3,001–10,000  7,001–20,000 105  5.9 39.8 60.7
10,001–30,000 20,001–55,000 121 15.1 57.2 78.6
      >30,000       >55,000 121 47.9 77.7 94.4




study 3 yrs 6 yrs 9 yrs
        ≤500        ≤1,500 110  1.0  5.0 10.7
    501–3,000   1,501–7,000 180  2.3 14.9 33.2
 3,001–10,000  7,001–20,000 237  7.2 25.9 50.3
10,001–30,000 20,001–55,000 202 14.6 47.7 70.6










*Data from the Multicenter AIDS Cohort Study (MACS) (12 ).
†In this study, AIDS was defined according to the 1987 CDC definition and does not include
asymptomatic persons who have CD4+ T cells <200/mm3.
§MACS numbers reflect plasma HIV RNA values obtained by bDNA testing. RT-PCR values are
consistently 2–2.5–fold higher than bDNA values, as indicated.
¶Too few subjects were in the category to provide a reliable estimate of AIDS risk.
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TABLE 5. Indications for the initiation of antiretroviral therapy in the chronically
HIV-infected patient





Asymptomatic CD4+ T Cells <500/mm3
              or
HIV RNA >10,000 (bDNA)






shown in Table 4 and
willingness of the patient to
accept therapy.*
Asymptomatic CD4+ T Cells >500/mm3
              and
HIV RNA <10,000 (bDNA)
           or <20,000 (RT-PCR)




*Some experts would observe patients whose CD4+ T cell counts are between 350–500/mm3
and HIV RNA levels <10,000 (bDNA) or <20,000 (RT-PCR).
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TABLE 6. Recommended antiretroviral agents for treatment of established HIV
infection
Preferred: Strong evidence of clinical benefit and/or sustained suppression of plasma viral load
(2, 34, 35 )
One choice each from column A and column B. Drugs are listed in random, not priority, order:
Column A Column B
Indinavir (AI) ZDV + ddl (AI)
Nelfinavir (AII) d4T  + ddl (AII)
Ritonavir (AI) ZDV + ddC (AI)




d4T  + 3TC§ (AII)
Alternative: Less likely to provide sustained virus suppression; (36–38 )
    1 NNRTI (Nevirapine)¶ + 2 NRTIs (Column B, above) (BII)
    Saquinavir-HGC + 2 NRTIs (Column B, above) (BI)
Not generally recommended: Strong evidence of clinical benefit, but initial virus suppression is
not sustained in most patients (39,40 )
    2 NRTIs (Column B, above) (CI)
Not recommended**: Evidence against use, virologically undesirable, or overlapping toxicities
    All monotherapies (DI)
    d4T + ZDV (DI)
    ddC + ddI†† (DII)
    ddC + d4T†† (DII)
    ddC + 3TC (DII)
 *Virologic data and clinical experience with saquinavir-sgc are limited in comparison with
other protease inhibitors.
†Use of ritonavir 400 mg b.i.d. with saquinavir soft-gel formulation (Fortovase) 400 mg b.i.d.
results in similar areas under the curve (AUC) of drug and antiretroviral activity as when
using 400 mg b.i.d. of Invirase  in combination with ritonavir. However, this combination
with Fortovase  has not been extensively studied and gastrointestinal toxicity may be
greater when using Fortovase .
§High-level resistance to 3TC develops within 2–4 wks. in partially suppressive regimens;
optimal use is in three-drug antiretroviral combinations that reduce viral load to <500
copies/mL.
¶The only combination of 2 NRTIs + 1 NNRTI that has been shown to suppress viremia to
undetectable levels in the majority of patients is ZDV+ddI+Nevirapine. This combination
was studied in antiretroviral-naive persons (36 ).
**ZDV monotherapy may be considered for prophylactic use in pregnant women who have
low viral load and high CD4+ T cell counts to prevent perinatal transmission (see
“Considerations for Antiretroviral Therapy in the Pregnant HIV-Infected Woman” on pages
59–62).
††This combination of NRTIs is not recommended based on lack of clinical data using the
combination and/or overlapping toxicities.















TABLE 7. Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs)
Generic name
Zidovudine
(AZT, ZDV) Didanosine (ddI) Zalcitabine (ddC) Stavudine (d4T) Lamivudine (3TC)
Trade name Retrovir Videx HIVID Zerit Epivir
Dosing
recommendations
200 mg t.i.d. or 300





<60 kg: 125 mg b.i.d.
0.75 mg t.i.d. >60 kg: 40 mg b.i.d.
<60 kg: 30 mg b.i.d.
150 mg b.i.d.
<50 kg: 2 mg/kg b.i.d.
or with ZDV as
Combivir , 1 b.i.d.
Oral bioavailability 60% Tablet: 40%
Powder: 30%
85% 86% 86%
Serum half-life 1.1 hr. 1.6 hr. 1.2 hr. 1.0 hr. 3–6 hrs.
Intracellular half-life 3 hrs. 25–40 hrs. 3 hrs. 3.5 hrs. 12 hrs.




Renal excretion 50% Renal excretion 70% Renal excretion 50% Renal excretion
unchanged


















TABLE 8. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Generic name Nevirapine Delavirdine
Trade name Viramune Rescriptor
Form 200 mg tabs 100 mg tabs
Dosing recommendations 200 mg po q.d. x 14 days, 
then 200 mg po b.i.d.
400 mg po t.i.d. (four 100 mg
tabs in ≥3 oz. water to produce
slurry)
Oral bioavailability >90% 85%
Serum half-life 25–30 hrs. 5.8 hrs.
Elimination Metabolized by cytochrome
p450; 80% excreted in urine
(glucuronidated metabolites,
<5% unchanged); 10% in feces
Metabolized by cytochrome
p450; 51% excreted in urine
(<5% unchanged); 44% in feces




• The following drugs have
suspected interactions that
























Adverse events Rash; increased transaminase
levels; hepatitis
Rash; headaches















TABLE 9. Characteristics of protease inhibitors (PIs)
Generic name Indinavir Ritonavir Saquinavir Nelfinavir
Trade name Crixivan Norvir Invirase Fortovase Viracept
Form 200-, 400-mg caps 100-mg caps
600 mg/7.5 mL po
solution





Take 1 hr. before or 2
hrs. after meals; may
take with skim milk
or low-fat meal.
600 mg q12h*
Take with food if
possible.
600 mg t.i.d.*
Take with large meal.
1,200 mg t.i.d.
Take with large meal.
750 mg t.i.d.
Take with food (meal
or light snack).





Serum half-life 1.5–2 hrs. 3–5 hrs. 1–2 hrs. 1–2 hrs. 3.5–5 hrs.
Route of metabolism P450 cytochrome 3A4 P450 cytochrome
3A4>2D6
P450 cytochrome 3A4 P450 cytochrome 3A4 P450 cytochrome 3A4
Storage Room temperature Refrigerate capsules;
refrigeration for oral
solution is preferred
but not required if
used within 30 days.
Room temperature Refrigerate or store
at room temperature
























































































































































































*Dose escalation for ritonavir: Day 1–2: 300 mg b.i.d.; day 3–5: 400 mg b.i.d.; day 6–13: 500 mg b.i.d.; day 14: 600 mg b.i.d. Combination
treatment regimen with saquinavir (400–600 mg po b.i.d.) plus ritonavir (400–600 mg po b.i.d.).
†Drugs contraindicated for concurrent use with ritonavir: amioderone (Cordonrone), astemizole (Hismanal), bepridil (Vascar), bupropion
(Wellbutin), cisapride (Propulsid), clorazepate (Tranxene), clozapine (Clozaril),diazepam (Valium), encainide (Enkaid), estazolam (ProSom),
flecainide (Tambocor), flurazepam (Dalmane), meperidine (Demerol), midazolam (Versed), piroxicam (Feldene), propoxyphene (Darvon),
propafenone (Rythmol), quinidine, rifabutin, terfenadine (Seldane), triazolam (Halcion), zolpidem (Ambien), ergot alkaloids.
§Decrease indinavir to 600 mg q8h.















TABLE 10. Drugs that should not be used with protease inhibitors
Drugs     




Fortovase ) Nelfinavir Alternatives
Analgesics (none) meperidine prioxicam
propoxyphene
(none) (none) ASA, oxycodon
acetaminophen
Cardiac (none) amioderone encainide
flecainide propafenone
quinidine
(none) (none) limited experience
Antimycobacterial rifampin rifabutin† rifampin
rifabutin

















GI cisapride cisapride cisapride cisapride limited experience
Antidepressant (none) bupropion (none) (none) fluoxetine, desipramine




















*The contraindicated drugs listed are based on theoretical considerations. Thus, drugs with low therapeutic indices yet with suspected
major metabolic contribution from cytochrome P450 3A, CYP2D6, or unknown pathways are included in this table. Actual interactions
may or may not occur in patients.
†Reduce rifabutin dose to one fourth of the standard dose.
















TABLE 11. Drug interactions between protease inhibitors and other drugs; drug interactions requiring dose modifications
Indinavir Ritonavir Saquinavir* Nelfinavir
Fluconazole No dose change No dose change No data No dose change
Ketoconazole and
itraconazole






3-fold; no dose change†.
No dose change
Rifabutin Reduce rifabutin to one
half dose: 150 mg q.d.
Consider alternative drug
or reduce dose to one
fourth of standard dose.
Not recommended with
either Invirase  or
Fortovase .
Reduce rifabutin to one
half dose: 150 mg q.d.
Rifampin Contraindicated Unknown§ Not recommended with
either Invirase  or
Fortovase .
Contraindicated












Miscellaneous Grapefruit juice reduces







*Several drug interaction studies have been completed with saquinavir given as Invirase  or Fortovase .   Results from studies
conducted with Invirase  may not be applicable to Fortovase .
†Conducted with Invirase .
§Rifampin reduces ritonavir 35%. Increased ritonavir dose or use of ritonavir in combination therapy is strongly recommended.  The effect
of ritonavir on rifampin is unknown. Used concurrently, increased liver toxicity may occur. Therefore, patients on ritonavir and rifampin















TABLE 12. Drug interactions: protease inhibitors and non-nucleoside reverse transcriptase inhibitors — effect of drug on
levels/dose
Drug affected Indinavir Ritonavir Saquinavir* Nelfinavir Nevirapine Delavirdine









Dose: IDV 600 mg
q8h




400 mg b.i.d. +






Levels: RTV ↑70% 
Dose: no data




















































— Do not use
together
Delavirdine (DLV) Levels: IDV ↑40%


















*Several drug interaction studies have been completed with saquinavir given as Invirase  or Fortovase .   Results from studies
conducted with Invirase  may not be applicable to Fortovase .
†Conducted with Invirase .
§Conducted with Fortovase .
• Criteria for changing therapy include a suboptimal reduction in plasma viremia after
initiation of therapy, reappearance of viremia after suppression to undetectable,
substantial increases in plasma viremia from the nadir of suppression, and declin-
ing CD4 + T cell numbers. Refer to the more extensive discussion of these criteria in
“Criteria for Changing Therapy” on pages 53–54.
• When the decision to change therapy is based on viral load determination, it is pref-
erable to confirm with a second viral load test.
• Distinguish between the need to change a regimen because of drug intolerance or
inability to comply with the regimen versus failure to achieve the goal of sustained
viral suppression; single agents can be changed or dose reduced in the event of
drug intolerance.
• In general, do not change a single drug or add a single drug to a failing regimen; it
is important to use at least two new drugs and preferably to use an entirely new
regimen with at least three new drugs. 
• Many patients have limited options for new regimens of desired potency; in some
of these cases, it is rational to continue the prior regimen if partial viral suppression
was achieved.
• In some cases, regimens identified as suboptimal for initial therapy are rational due
to limitations imposed by toxicity, intolerance, or nonadherence.  This especially ap-
plies in late-stage disease.  For patients with no rational alternative options who
have virologic failure with return of viral load to baseline (pretreatment levels) and
a declining CD4+ T cell count, discontinuation of antiretroviral therapy should be
considered.
• Experience is limited with regimens using combinations of two protease inhibitors
or combinations of protease inhibitors with nevirapine or delavirdine;  for patients
with limited options due to drug intolerance or suspected resistance, these regi-
mens provide possible alternative treatment options.
• There is limited information about the value of restarting a drug that the patient has
previously received.  The experience with zidovudine is that resistant strains are
often replaced with “wild-type” zidovudine sensitive strains when zidovudine treat-
ment is stopped, but resistance recurs rapidly if zidovudine is restarted. Although
preliminary evidence indicates that this occurs with indinavir, it is not known if simi-
lar problems apply to other nucleoside analogues, protease inhibitors, or NNRTIs,
but a conservative stance is that they probably do.  
• Avoid changing from ritonavir to indinavir or vice versa for drug failure, because
high-level cross-resistance is likely.
• Avoid changing from nevirapine to delavirdine or vice versa for drug failure, be-
cause high-level cross-resistance is likely.
• The decision to change therapy and the choice of a new regimen require that the
clinician have considerable expertise in the care of persons living with HIV infection.
Physicians who are less experienced in the care of persons with HIV infection are
strongly encouraged to obtain assistance through consultation with or referral to a
clinician who has considerable expertise in the care of HIV-infected patients.
Table 13. Guidelines for changing an antiretroviral regimen for suspected drug failure
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TABLE 14. Possible regimens for patients who have failed antiretroviral therapy: a
work in progress*
Prior regimen New regimen (not listed in priority order)
2 NRTIs + 2 new NRTIs +
  Nelfinavir (NFV)   RTV; or IDV; or SQV + RTV; or NNRTI† +
   RTV; or NNRTI + IDV§
  Ritonavir (RTV)   SQV + RTV§; NFV + NNRTI; or NFV + SQV
  Indinavir (IDV)   SQV + RTV; NFV + NNRTI; or NFV + SQV
  Saquinavir (SQV)   RTV + SQV; or NNRTI + IDV
2 NRTIs + NNRTI 2 new NRTIs + a protease inhibitor
2 NRTIs 2 new NRTIs + a protease inhibitor
2 new NRTIs + RTV + SQV
1 new NRTI + 1 NNRTI + a protease inhibitor
2 protease inhibitors + NNRTI
1 NRTI 2 new NRTIs + a protease inhibitor
2 new NRTIs + NNRTI
1 new NRTI + 1 NNRTI + a protease inhibitor
*These alternative regimens have not been proven to be clinically effective and were arrived
at through discussion by the panel of theoretically possible alternative treatments and the
elimination of those alternatives with evidence of being ineffective.  Clinical trials in this area
are urgently needed.
†Of the two available NNRTIs, clinical trials support a preference for nevirapine over delavirdine
based on results of viral load assays.  These two agents have opposite effects on the CYP450
pathway, and this must be considered in combining these drugs with other agents.
§There are some clinical trials that have yielded viral burden data to support this recommen-
dation.





 Erythematous maculopapular with lesions on face and trunk and sometimes
   extremities, including palms and soles
 Mucocutaneous ulceration involving mouth, esophagus, or genitals
• Myalgia or arthralgia (54%)
• Diarrhea (32%)
• Headache (32%)
• Nausea and vomiting (27%)
• Hepatosplenomegaly (14%)
• Thrush   (12%)
• Weight Loss 
• Neurologic symptoms (12%)
 Meningoencephalitis or aseptic meningitis




 Cognitive impairment or psychosis
*Adapted from reference 19.
TABLE 15. Acute retroviral syndrome: associated signs and symptoms and expected
frequency*
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Stavudine C Yes (rhesus) [0.76] Not completed Negative (but
sternal bone
calcium decreases)




Saquinavir B Unknown Not completed Negative
Indinavir C Yes (rats)
(“Significant” in
rats; low in rabbits)
Not completed Negative (but extra
ribs in rats)




Not completed Negative (but
cryptorchidism in
rats)§
Nelfinavir B Unknown Not completed Negative
Neviparine C Yes (human) [~1.0] Not completed Negative




Not completed Ventricular septal
defect
*Food and Drug Administration-defined pregnancy categories are:  A = Adequate and well-con-
trolled studies of pregnant women fail to demonstrate a risk to the fetus during the first
trimester of pregnancy (and there is no evidence of risk during later trimesters); B = Animal
reproduction studies fail to demonstrate a risk to the fetus, and adequate but well-controlled
studies of pregnant women have not been conducted; C = Safety in human pregnancy has
not been determined, animal studies are either positive for fetal risk or have not been con-
ducted, and the drug should not be used unless the potential benefit outweighs the potential
risk to the fetus; D = Positive evidence of human fetal risk based on adverse reaction data
from investigational or marketing experiences, but the potential benefits from the use of the
drug in pregnant women may be acceptable despite its potential risks; X = Studies in animals
or reports of adverse reactions have indicated that the risk associated with the use of the drug
for pregnant women clearly outweighs any possible benefit.
†Despite certain animal data indicating potential teratogenicity of ZDV when near-lethal doses
are given to pregnant rodents, considerable human data are available to date indicating that
the risk to the fetus, if any, is extremely small when given to the pregnant mother beyond 14
weeks’ gestation.  Follow-up for up to age 6 years for 734 infants born to HIV-infected women
who had in utero exposure to ZDV has not demonstrated any tumor development (44 ) .
However, no data are available with longer follow-up to evaluate for late effects.
§These are effects seen only at maternally toxic doses.
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